Estrogenic endocrine disruptors: Molecular mechanisms of action

Environment International

Volumn 83, Issue , 2015, Pages 11-40

  Kiyama, Ryoiti ^a   Wada Kiyama, Yuko ^b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Endocrine disruptor; Estrogen action; Molecular mechanism; Signal transduction; Techonology; Toxicity pathway

Indexed keywords

RISK MANAGEMENT; SIGNAL TRANSDUCTION; TOXICITY;

ENDOCRINE DISRUPTOR; ESTROGEN ACTION; ESTROGENIC CHEMICALS; ESTROGENIC ENDOCRINE DISRUPTORS; MOLECULAR MECHANISM; SIGNALING PATHWAYS; TECHONOLOGY; TOXICITY TESTING;

RISK ASSESSMENT;

CELL NUCLEUS RECEPTOR; ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN DERIVATIVE; FOOD ADDITIVE; MEMBRANE RECEPTOR; NON PHENOLIC ESTROGEN DERIVATIVE; PESTICIDE; PHENOLIC ESTROGEN; PLASTICIZER; UNCLASSIFIED DRUG;

ASSAY; ENDOCRINE DISRUPTOR; ESTROGENIC COMPOUND; MOLECULAR ANALYSIS; TECHNOLOGY; TOXICITY TEST;

APOPTOSIS; ASSAY; AUTOCRINE EFFECT; CARCINOGENESIS; CELL ASSAY; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; DIET SUPPLEMENTATION; ESTROGEN ACTIVITY; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PARACRINE SIGNALING; POLLUTANT; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR BINDING ASSAY; REPORTER GENE ASSAY; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXICITY TESTING; TRANSCRIPTION ASSAY; TWO HYBRID SYSTEM; ANIMAL; DRUG EFFECTS; METABOLISM;

ANIMALS; ENDOCRINE DISRUPTORS; ESTROGENS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84930932671     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2015.05.012     Document Type: Review

References (513)

1. Abdelrahim M., Ariazi E., Kim K., Khan S., Barhoumi R., Burghardt R., Liu S., Hill D., Finnell R., Wlodarczyk B., Jordan V.C., Safe S. 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Cancer Res. 2006, 66(4):2459-2467.
2. Adeleye Y., Andersen M., Clewell R., Davies M., Dent M., Edwards S., Fowler P., Malcomber S., Nicol B., Scott A., Scott S., Sun B., Westmoreland C., White A., Zhang Q., Carmichael P.L. Implementing Toxicity Testing in the 21st Century (TT21C): making safety decisions using toxicity pathways, and progress in a prototype risk assessment. Toxicology 2015, 332:102-111.
3. Ahmad A., Banerjee S., Wang Z., Kong D., Sarkar F.H. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J. Cell. Biochem. 2008, 105(6):1461-1471.
4. Ahmed S., Valen E., Sandelin A., Matthews J. Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. Toxicol. Sci. 2009, 111(2):254-266.
5. Akama K.T., Thompson L.I., Milner T.A., McEwen B.S. Post-synaptic density-95 (PSD-95) binding capacity of G-protein-coupled receptor 30 (GPR30), an estrogen receptor that can be identified in hippocampal dendritic spines. J. Biol. Chem. 2013, 288(9):6438-6450.
6. Alarid E.T., Preisler-Mashek M.T., Solodin N.M. Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 2003, 144(8):3469-3476.
7. Ali Z., Khan S.I., Khan I.A. Soyasaponin Bh, a triterpene saponin containing a unique hemiacetal-functional five-membered ring from Glycine max (soybeans). Planta Med. 2009, 75(4):371-374.
8. Ali I., Damdimopoulou P., Stenius U., Adamsson A., Mäkelä S.I., Åkesson A., Berglund M., Håkansson H., Halldin K. Cadmium-induced effects on cellular signaling pathways in the liver of transgenic estrogen reporter mice. Toxicol. Sci. 2012, 127(1):66-75.
9. Alimirah F., Peng X., Yuan L., Mehta R.R., von Knethen A., Choubey D., Mehta R.G. Crosstalk between the peroxisome proliferator-activated receptor γ (PPARγ) and the vitamin D receptor (VDR) in human breast cancer cells: PPARγ binds to VDR and inhibits 1α,25-dihydroxyvitamin D3 mediated transactivation. Exp. Cell Res. 2012, 318(19):2490-2497.
10. Allinson M., Shiraishi F., Allinson G. A comparison of recombinant receptor-reporter gene bioassays and a total estrogen enzyme linked immunosorbent assay for the rapid screening of estrogenic activity in natural and waste waters. Bull. Environ. Contam. Toxicol. 2011, 86(5):461-464.
11. Andersen H.R., Vinggaard A.M., Rasmussen T.H., Gjermandsen I.M., Bonefeld-Jørgensen E.C. Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity in vitro. Toxicol. Appl. Pharmacol. 2002, 179(1):1-12.
12. Andersen H.R., Bonefeld-Jørgensen E.C., Nielsen F., Jarfeldt K., Jayatissa M.N., Vinggaard A.M. Estrogenic effects in vitro and in vivo of the fungicide fenarimol. Toxicol. Lett. 2006, 163(2):142-152.
13. Anita Y., Radifar M., Kardono L.B., Hanafi M., Istyastono E.P. Structure-based design of eugenol analogs as potential estrogen receptor antagonists. Bioinformation 2012, 8(19):901-906.
14. Anstead G.M., Kym P.R. Benz[a]anthracene diols: predicted carcinogenicity and structure-estrogen receptor binding affinity relationships. Steroids 1995, 60(5):383-394.
15. Arbo M.D., Franco M.T., Larentis E.R., Garcia S.C., Sebben V.C., Leal M.B., Dallegrave E., Limberger R.P. Screening for in vivo (anti)estrogenic activity of ephedrine and p-synephrine and their natural sources Ephedra sinica Stapf. (Ephedraceae) and Citrus aurantium L. (Rutaceae) in rats. Arch. Toxicol. 2009, 83(1):95-99.
16. Ariazi E.A., Jordan V.C. Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr. Top. Med. Chem. 2006, 6(3):203-215.
17. Armstrong A.F., Valliant J.F. The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy. Dalton Trans. 2007, 38:4240-4251.
18. Arnold S.F., Robinson M.K., Notides A.C., Guillette L.J., McLachlan J.A. A yeast estrogen screen for examining the relative exposure of cells to natural and xenoestrogens. Environ. Health Perspect. 1996, 104(5):544-548.
19. Arulmozhiraja S., Shiraishi F., Okumura T., Iida M., Takigami H., Edmonds J.S., Morita M. Structural requirements for the interaction of 91 hydroxylated polychlorinated biphenyls with estrogen and thyroid hormone receptors. Toxicol. Sci. 2005, 84(1):49-62.
20. Ashok B.T., Chen Y., Liu X., Bradlow H.L., Mittelman A., Tiwari R.K. Abrogation of estrogen-mediated cellular and biochemical effects by indole-3-carbinol. Nutr. Cancer 2001, 41(1-2):180-187.
21. Axon A., May F.E., Gaughan L.E., Williams F.M., Blain P.G., Wright M.C. Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology 2012, 298(1-3):40-51.
22. Babiker F.A., De Windt L.J., van Eickels M., Thijssen V., Bronsaer R.J., Grohé C., van Bilsen M., Doevendans P.A. 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation 2004, 109(2):269-276.
23. Bachmeier B.E., Mirisola V., Romeo F., Generoso L., Esposito A., Dell'eva R., Blengio F., Killian P.H., Albini A., Pfeffer U. Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin. Cell. Physiol. Biochem. 2010, 26(3):471-482.
24. Baker M.E. What are the physiological estrogens?. Steroids 2013, 78(3):337-340.
25. Baker M.E., Vidal-Dorsch D.E., Ribecco C., Sprague L.J., Angert M., Lekmine N., Ludka C., Martella A., Ricciardelli E., Bay S.M., Gully J.R., Kelley K.M., Schlenk D., Carnevali O., Šášik R., Hardiman G. Molecular analysis of endocrine disruption in hornyhead turbot at wastewater outfalls in southern california using a second generation multi-species microarray. PLoS One 2013, 8(9):e75553.
26. Ballaré C., Vallejo G., Vicent G.P., Saragüeta P., Beato M. Progesterone signaling in breast and endometrium. J. Steroid Biochem. Mol. Biol. 2006, 102(1-5):2-10.
27. Band A.M., Laiho M. Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2011, 16(2):109-115.
28. Barbarisi A., Petillo O., Di Lieto A., Melone M.A., Margarucci S., Cannas M., Peluso G. 17-Beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J. Cell. Physiol. 2001, 186(3):414-424.
29. Belguise K., Guo S., Sonenshein G.E. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Cancer Res. 2007, 67(12):5763-5770.
30. Berthier A., Girard C., Grandvuillemin A., Muyard F., Skaltsounis A.L., Jouvenot M., Delage-Mourroux R. Effect of 7-O-beta-d-glucopyranosylchrysin and its aglycone chrysin isolated from Podocytisus caramanicus on estrogen receptor alpha transcriptional activity. Planta Med. 2007, 73(14):1447-1451.
31. Bhargavan B., Singh D., Gautam A.K., Mishra J.S., Kumar A., Goel A., Dixit M., Pandey R., Manickavasagam L., Dwivedi S.D., Chakravarti B., Jain G.K., Ramachandran R., Maurya R., Trivedi A., Chattopadhyay N., Sanyal S. Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor β-mediated osteogenic action of medicarpin. J. Nutr. Biochem. 2012, 23(1):27-38.
32. Bhavnani B.R., Stanczyk F.Z. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J. Steroid Biochem. Mol. Biol. 2014, 142:16-29.
33. Bhavnani B.R., Tam S.P., Lu X. Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta. Endocrinology 2008, 149(10):4857-4870.
34. Biberger C., von Angerer E. 2-Phenylindoles with sulfur containing side chains. Estrogen receptor affinity, antiestrogenic potency, and antitumor activity. J. Steroid Biochem. Mol. Biol. 1996, 58(1):31-43.
35. Boettger-Tong H.L., Stancel G.M. Retinoic acid inhibits estrogen-induced uterine stromal and myometrial cell proliferation. Endocrinology 1995, 136(7):2975-2983.
36. Boldrin P., Resende F., Höhne A., de Camargo M., Espanha L., Nogueira C., Melo M., Vilegas W., Varanda E. Estrogenic and mutagenic activities of Crotalaria pallida measured by recombinant yeast assay and Ames test. BMC Complement. Altern. Med. 2013, 13(1):216.
37. Boudot A., Kerdivel G., Habauzit D., Eeckhoute J., Le Dily F., Flouriot G., Samson M., Pakdel F. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One 2011, 6(6):e20898.
38. Boué S.M., Tilghman S.L., Elliott S., Zimmerman M.C., Williams K.Y., Payton-Stewart F., Miraflor A.P., Howell M.H., Shih B.Y., Carter-Wientjes C.H., Segar C., Beckman B.S., Wiese T.E., Cleveland T.E., McLachlan J.A., Burow M.E. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 2009, 150(5):2446-2453.
39. Bourque M., Morissette M., Di Paolo T. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiol. Aging 2014, 35(10):2347-2356.
40. Bovee T.F., Helsdingen R.J., Rietjens I.M., Keijer J., Hoogenboom R.L. Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. J. Steroid Biochem. Mol. Biol. 2004, 91(3):99-109.
41. Brailoiu G.C., Benamar K., Arterburn J.B., Gao E., Rabinowitz J.E., Koch W.J., Brailoiu E. Aldosterone increases cardiac vagal tone via G protein-coupled oestrogen receptor activation. J. Physiol. 2013, 591(Pt 17):4223-4235.
42. Brander S.M., He G., Smalling K.L., Denison M.S., Cherr G.N. The in vivo estrogenic and in vitro anti-estrogenic activity of permethrin and bifenthrin. Environ. Toxicol. Chem. 2012, 31(12):2848-2855.
43. Brennan J.C., Denison M.S., Holstege D.M., Magiatis P., Dallas J.L., Gutierrez E.G., Soshilov A.A., Millam J.R. 2,3-Cis-2R,3R-(-)-epiafzelechin-3-O-p-coumarate, a novel flavan-3-ol isolated from Fallopia convolvulus seed, is an estrogen receptor agonist in human cell lines. BMC Complement. Altern. Med. 2013, 13:133.
44. Brinton R.D., Proffitt P., Tran J., Luu R. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptor-dependent mechanism. Exp. Neurol. 1997, 147(2):211-220.
45. Briz V., Molina-Molina J.M., Sánchez-Redondo S., Fernández M.F., Grimalt J.O., Olea N., Rodríguez-Farré E., Suñol C. Differential estrogenic effects of the persistent organochlorine pesticides dieldrin, endosulfan, and lindane in primary neuronal cultures. Toxicol. Sci. 2011, 120(2):413-427.
46. Bulayeva N.N., Watson C.S. Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ. Health Perspect. 2004, 112(15):1481-1487.
47. Bulzomi P., Bolli A., Galluzzo P., Acconcia F., Ascenzi P., Marino M. The naringenin-induced proapoptotic effect in breast cancer cell lines holds out against a high bisphenol a background. IUBMB Life 2012, 64(8):690-696.
48. Bulzomi P., Galluzzo P., Bolli A., Leone S., Acconcia F., Marino M. The pro-apoptotic effect of quercetin in cancer cell lines requires ERβ-dependent signals. J. Cell. Physiol. 2012, 227(5):1891-1898.
49. Burow M.E., Boue S.M., Collins-Burow B.M., Melnik L.I., Duong B.N., Carter-Wientjes C.H., Li S., Wiese T.E., Cleveland T.E., McLachlan J.A. Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J. Clin. Endocrinol. Metab. 2001, 86(4):1750-1758.
50. Byrne C., Divekar S.D., Storchan G.B., Parodi D.A., Martin M.B. Metals and breast cancer. J. Mammary Gland Biol. Neoplasia 2013, 18(1):63-73.
51. Cao L., Gao H., Li P., Gui S., Zhang Y. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells. Tumour Biol. 2014, 35(6):5121-5127.
52. Chalabi N., Le Corre L., Maurizis J.C., Bignon Y.J., Bernard-Gallon D.J. The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression. Eur. J. Cancer 2004, 40(11):1768-1775.
53. Chalopin M., Tesse A., Martínez M.C., Rognan D., Arnal J.F., Andriantsitohaina R. Estrogen receptor alpha as a key target of red wine polyphenols action on the endothelium. PLoS One 2010, 5(1):e8554.
54. Chaloupka K., Krishnan V., Safe S. Polynuclear aromatic hydrocarbon carcinogens as antiestrogens in MCF-7 human breast cancer cells: role of the Ah receptor. Carcinogenesis 1992, 13(12):2233-2239.
55. Chan H.Y., Yao X., Tsang S.Y., Bourreau J.P., Chan F.L., Huang Y. Isoproterenol amplifies 17 beta-estradiol-mediated vasorelaxation: role of endothelium/nitric oxide and cyclic AMP. Cardiovasc. Res. 2002, 53(3):627-633.
56. Chan M.Y., Wai Man G., Chen Z.Y., Wang J., Leung L.K. Oestrogen receptor alpha is required for biochanin A-induced apolipoprotein A-1 mRNA expression in HepG2 cells. Br. J. Nutr. 2007, 98(3):534-539.
57. Chandsawangbhuwana C., Baker M.E. 3D models of human ERα and ERβ complexed with coumestrol. Steroids 2014, 80:37-43.
58. Chang E.J., Lee W.J., Cho S.H., Choi S.W. Proliferative effects of flavan-3-ols and propelargonidins from rhizomes of Drynaria fortunei on MCF-7 and osteoblastic cells. Arch. Pharm. Res. 2003, 26(8):620-630.
59. Chang C.J., Chiu J.H., Tseng L.M., Chang C.H., Chien T.M., Wu C.W., Lui W.Y. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur. J. Clin. Investig. 2006, 36(8):588-596.
60. Chatterjee A., Chatterji U. Arsenic abrogates the estrogen-signaling pathway in the rat uterus. Reprod. Biol. Endocrinol. 2010, 8:80.
61. Chatterjee S., Ray A., Bagchi P., Deb C. Estrogenic effects of aldrin and quinalphos in rats. Bull. Environ. Contam. Toxicol. 1992, 48(1):125-130.
62. Chen Y. Organophosphate-induced brain damage: mechanisms, neuropsychiatric and neurological consequences, and potential therapeutic strategies. Neurotoxicology 2012, 33(3):391-400.
63. Chen J., Sun L. Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells. Horm. Metab. Res. 2012, 44(13):943-948.
64. Chen H., Xiao J., Hu G., Zhou J., Xiao H., Wang X. Estrogenicity of organophosphorus and pyrethroid pesticides. J. Toxicol. Environ. Health A 2002, 65(19):1419-1435.
65. Chen W.F., Gao Q.G., Dai Z.J., Kung A.W., Guo D.A., Wong M.S. Estrogenic effects of ginsenoside Rg1 in endometrial cells in vitro were not observed in immature CD-1 mice or ovariectomized mice model. Menopause 2012, 19(9):1052-1061.
66. Chen J., Zhao X., Ye Y., Wang Y., Tian J. Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin. Cell. Physiol. Biochem. 2013, 32(6):1790-1797.
67. Chen J., Hou R., Zhang X., Ye Y., Wang Y., Tian J. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways. PLoS One 2014, 9(3):e91245.
68. Chen Y., Li Z., He Y., Shang D., Pan J., Wang H., Chen H., Zhu Z., Wan L., Wang X. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol. Appl. Pharmacol. 2014, 275(2):176-181.
69. Chen X., Xu S., Tan T., Lee S.T., Cheng S.H., Lee F.W., Xu S.J., Ho K.C. Toxicity and estrogenic endocrine disrupting activity of phthalates and their mixtures. Int. J. Environ. Res. Public Health 2014, 11(3):3156-3168.
70. Cheng P., Kanterewicz B., Hershberger P.A., McCarty K.S., Day B.W., Nichols M. Inhibition of estrogen receptor alpha-mediated transcription by antiestrogenic 1,1-dichloro-2,2,3-triarylcyclopropanes. Mol. Pharmacol. 2004, 66(4):970-977.
71. Chimento A., Sirianni R., Casaburi I., Pezzi V. Role of estrogen receptors and g protein-coupled estrogen receptor in regulation of hypothalamus-pituitary-testis axis and spermatogenesis. Front. Endocrinol. (Lausanne) 2014, 5:1.
72. Chin L., Andersen J.N., Futreal P.A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 2011, 17(3):297-303.
73. Choe S.Y., Kim S.J., Kim H.G., Lee J.H., Choi Y., Lee H., Kim Y. Evaluation of estrogenicity of major heavy metals. Sci. Total Environ. 2003, 312(1-3):15-21.
74. Choi R.C., Zhu J.T., Yung A.W., Lee P.S., Xu S.L., Guo A.J., Zhu K.Y., Dong T.T., Tsim K.W. Synergistic action of flavonoids, baicalein, and daidzein in estrogenic and neuroprotective effects: a development of potential health products and therapeutic drugs against Alzheimer's disease. Evid. Based Complement. Alternat. Med. 2013, 2013:635694.
75. Chow S.K., Chan J.Y., Fung K.P. Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. J. Endocrinol. 2004, 182(2):325-337.
76. Chung H., Jung Y.M., Shin D.H., Lee J.Y., Oh M.Y., Kim H.J., Jang K.S., Jeon S.J., Son K.H., Kong G. Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int. J. Cancer 2008, 122(4):816-822.
77. Collins-Burow B.M., Burow M.E., Duong B.N., McLachlan J.A. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr. Cancer 2000, 38(2):229-244.
78. Collins-Burow B.M., Antoon J.W., Frigo D.E., Elliott S., Weldon C.B., Boue S.M., Beckman B.S., Curiel T.J., Alam J., McLachlan J.A., Burow M.E. Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J. Steroid Biochem. Mol. Biol. 2012, 132(1-2):186-193.
79. Comitato R., Nesaretnam K., Leoni G., Ambra R., Canali R., Bolli A., Marino M., Virgili F. A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERbeta signal transduction. Am. J. Physiol. Endocrinol. Metab. 2009, 297(2):E427-E437.
80. Commission of the European Communities Fifth report on the statistics on the number of animals used for experimental and other scientific purposes in the member states of the European Union. Report from the Commission to the Council and the European Parliament. COM(2007) 675 Final 2007, (November).
81. Connor K., Ramamoorthy K., Moore M., Mustain M., Chen I., Safe S., Zacharewski T., Gillesby B., Joyeux A., Balaguer P. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships. Toxicol. Appl. Pharmacol. 1997, 145(1):111-123.
82. Coronado M., De Haro H., Deng X., Rempel M.A., Lavado R., Schlenk D. Estrogenic activity and reproductive effects of the UV-filter oxybenzone (2-hydroxy-4-methoxyphenyl-methanone) in fish. Aquat. Toxicol. 2008, 90(3):182-187.
83. Cos S., González A., Martínez-Campa C., Mediavilla M.D., Alonso-González C., Sánchez-Barceló E.J. Melatonin as a selective estrogen enzyme modulator. Curr. Cancer Drug Targets 2008, 8(8):691-702.
84. Cosentino M., Marino F., Ferrari M., Rasini E., Bombelli R., Luini A., Legnaro M., Delle Canne M.G., Luzzani M., Crema F., Paracchini S., Lecchini S. Estrogenic activity of 7-hydroxymatairesinol potassium acetate (HMR/lignan) from Norway spruce (Picea abies) knots and of its active metabolite enterolactone in MCF-7 cells. Pharmacol. Res. 2007, 56(2):140-147.
85. Dang V.H., Choi K.C., Jeung E.B. Tetrabromodiphenyl ether (BDE 47) evokes estrogenicity and calbindin-D9k expression through an estrogen receptor-mediated pathway in the uterus of immature rats. Toxicol. Sci. 2007, 97(2):504-511.
86. De Angelis M., Stossi F., Waibel M., Katzenellenbogen B.S., Katzenellenbogen J.A. Isocoumarins as estrogen receptor beta selective ligands: isomers of isoflavone phytoestrogens and their metabolites. Bioorg. Med. Chem. 2005, 13(23):6529-6542.
87. de Medina P., Genovese S., Paillasse M.R., Mazaheri M., Caze-Subra S., Bystricky K., Curini M., Silvente-Poirot S., Epifano F., Poirot M. Auraptene is an inhibitor of cholesterol esterification and a modulator of estrogen receptors. Mol. Pharmacol. 2010, 78(5):827-836.
88. Denier X., Hill E.M., Rotchell J., Minier C. Estrogenic activity of cadmium, copper and zinc in the yeast estrogen screen. Toxicol. In Vitro 2009, 23(4):569-573.
89. Deroo B.J., Korach K.S. Estrogen receptors and human disease. J. Clin. Invest. 2006, 116(3):561-570.
90. Desaulniers D., Leingartner K., Zacharewski T., Foster W.G. Optimization of an MCF7-E3 cell proliferation assay and effects of environmental pollutants and industrial chemicals. Toxicol. In Vitro 1998, 12(4):409-422.
91. Dietsch V., Kalf G.F., Hazel B.A. Induction of granulocytic differentiation in myeloblasts by 17-beta-estradiol involves the leukotriene D4 receptor. Recept. Signal Transduct. 1996, 6(2):63-75.
92. Dong S., Terasaka S., Kiyama R. Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ. Pollut. 2011, 159(1):212-218.
93. Dong S., Furutani Y., Kimura S., Zhu Y., Kawabata K., Furutani M., Nishikawa T., Tanaka T., Masaki T., Matsuoka R., Kiyama R. Brefeldin A is an estrogenic, Erk1/2-activating component in the extract of Agaricus blazei mycelia. J. Agric. Food Chem. 2013, 61(1):128-136.
94. Dong W.H., Chen J.C., He Y.L., Xu J.J., Mei Y.A. Resveratrol inhibits K(v)2.2 currents through the estrogen receptor GPR30-mediated PKC pathway. Am. J. Physiol. Cell Physiol. 2013, 305(5):C547-C557.
95. Dorosh A., Děd L., Elzeinová F., Pěknicová J. Assessing oestrogenic effects of brominated flame retardants hexabromocyclododecane and tetrabromobisphenol A on MCF-7 cells. Folia Biol. (Praha) 2011, 57(1):35-39.
96. Dowdy J., Brower S., Miller M.R. Acetaminophen exhibits weak antiestrogenic activity in human endometrial adenocarcinoma (Ishikawa) cells. Toxicol. Sci. 2003, 72(1):57-65.
97. Du G., Shen O., Sun H., Fei J., Lu C., Song L., Xia Y., Wang S., Wang X. Assessing hormone receptor activities of pyrethroid insecticides and their metabolites in reporter gene assays. Toxicol. Sci. 2010, 116(1):58-66.
98. DuSell C.D., Nelson E.R., Wang X., Abdo J., Mödder U.I., Umetani M., Gesty-Palmer D., Javitt N.B., Khosla S., McDonnell D.P. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 2010, 151(8):3675-3685.
99. Eldridge J.C., Stevens J.T., Breckenridge C.B. Atrazine interaction with estrogen expression systems. Rev. Environ. Contam. Toxicol. 2008, 196:147-160.
100. El-Halawany A.M., Chung M.H., Nakamura N., Ma C.M., Nishihara T., Hattori M. Estrogenic and anti-estrogenic activities of Cassia tora phenolic constituents. Chem. Pharm. Bull. (Tokyo) 2007, 55(10):1476-1482.
101. Endo Y., Iijima T., Yamakoshi Y., Fukasawa H., Miyaura C., Inada M., Kubo A., Itai A. Potent estrogen agonists based on carborane as a hydrophobic skeletal structure. A new medicinal application of boron clusters. Chem. Biol. 2001, 8(4):341-355.
102. Escande A., Pillon A., Servant N., Cravedi J.P., Larrea F., Muhn P., Nicolas J.C., Cavaillès V., Balaguer P. Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta. Biochem. Pharmacol. 2006, 71(10):1459-1469.
103. Etique N., Grillier-Vuissoz I., Lecomte J., Flament S. Crosstalk between adenosine receptor (A2A isoform) and ERalpha mediates ethanol action in MCF-7 breast cancer cells. Oncol. Rep. 2009, 21(4):977-981.
104. Fan G.W., Zhang Y., Jiang X., Zhu Y., Wang B., Su L., Cao W., Zhang H., Gao X. Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and NF-κB-dependent pathways. Inflammation 2013, 36(6):1584-1591.
105. Fang J., Akwabi-Ameyaw A., Britton J.E., Katamreddy S.R., Navas F., Miller A.B., Williams S.P., Gray D.W., Orband-Miller L.A., Shearin J., Heyer D. Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands. Bioorg. Med. Chem. Lett. 2008, 18(18):5075-5077.
106. Fang C., Wu X., Huang Q., Liao Y., Liu L., Qiu L., Shen H., Dong S. PFOS elicits transcriptional responses of the ER, AHR and PPAR pathways in Oryzias melastigma in a stage-specific manner. Aquat. Toxicol. 2012, 106-107:9-19.
107. Farabegoli F., Barbi C., Lambertini E., Piva R. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect. Prev. 2007, 31(6):499-504.
108. Feng J., Shi Z., Ye Z. Effects of metabolites of the lignans enterolactone and enterodiol on osteoblastic differentiation of MG-63 cells. Biol. Pharm. Bull. 2008, 31(6):1067-1070.
109. Fernandes I., Faria A., Azevedo J., Soares S., Calhau C., De Freitas V., Mateus N. Influence of anthocyanins, derivative pigments and other catechol and pyrogallol-type phenolics on breast cancer cell proliferation. J. Agric. Food Chem. 2010, 58(6):3785-3792.
110. Fernandez J.W., Rezai-Zadeh K., Obregon D., Tan J. EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. FEBS Lett. 2010, 584(19):4259-4267.
111. Fielden M.R., Chen I., Chittim B., Safe S.H., Zacharewski T.R. Examination of the estrogenicity of 2,4,6,2',6'-pentachlorobiphenyl (PCB 104), its hydroxylated metabolite 2,4,6,2',6'-pentachloro-4-biphenylol (HO-PCB 104), and a further chlorinated derivative, 2,4,6,2',4',6'-hexachlorobiphenyl (PCB 155). Environ. Health Perspect. 1997, 105(11):1238-1248.
112. Fillmore C.M., Gupta P.B., Rudnick J.A., Caballero S., Keller P.J., Lander E.S., Kuperwasser C. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(50):21737-21742.
113. Finlay G.A., Hunter D.S., Walker C.L., Paulson K.E., Fanburg B.L. Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression. Am. J. Physiol. Cell Physiol. 2003, 285(2):C409-C418.
114. Fort D.J., Rogers R.L., Paul R.R., Miller M.F., Clark P., Stover E.L., Yoshioko J., Quimby F., Sower S.A., Reed K.L., Babbitt K.J., Rolland R. Effects of pond water, sediment and sediment extract samples from New Hampshire, USA on early Xenopus development and metamorphosis: comparison to native species. J. Appl. Toxicol. 2001, 21(3):199-209.
115. Fox E.M., Kuba M.G., Miller T.W., Davies B.R., Arteaga C.L. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res. 2013, 15(4):R55.
116. Frazier-Jessen M.R., Mott F.J., Witte P.L., Kovacs E.J. Estrogen suppression of connective tissue deposition in a murine model of peritoneal adhesion formation. J. Immunol. 1996, 156(8):3036-3042.
117. Furuta C., Suzuki A.K., Taneda S., Kamata K., Hayashi H., Mori Y., Li C., Watanabe G., Taya K. Estrogenic activities of nitrophenols in diesel exhaust particles. Biol. Reprod. 2004, 70(5):1527-1533.
118. Gaido K.W., Leonard L.S., Maness S.C., Hall J.M., McDonnell D.P., Saville B., Safe S. Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta. Endocrinology 1999, 140(12):5746-5753.
119. Gallet M., Vanacker J.M. ERR receptors as potential targets in osteoporosis. Trends Endocrinol. Metab. 2010, 21(10):637-641.
120. Galluzzo P., Ascenzi P., Bulzomi P., Marino M. The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor alpha-palmitoylation. Endocrinology 2008, 149(5):2567-2575.
121. Gantus M.A., Alves L.M., Stipursky J., Souza E.C., Teodoro A.J., Alves T.R., Carvalho D.P., Martinez A.M., Gomes F.C., Nasciutti L.E. Estradiol modulates TGF-β1 expression and its signaling pathway in thyroid stromal cells. Mol. Cell. Endocrinol. 2011, 337(1-2):71-79.
122. Gao Q.G., Chen W.F., Xie J.X., Wong M.S. Ginsenoside Rg1 protects against 6-OHDA-induced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-I receptor and estrogen receptor pathways. J. Neurochem. 2009, 109(5):1338-1347.
123. Gao Y., Huang E., Zhang H., Wang J., Wu N., Chen X., Wang N., Wen S., Nan G., Deng F., Liao Z., Wu D., Zhang B., Zhang J., Haydon R.C., Luu H.H., Shi L.L., He T.C. Crosstalk between Wnt/β-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells. PLoS One 2013, 8(12):e82436.
124. Gao Q.G., Chan H.Y., Man C.W., Wong M.S. Differential ERα-mediated rapid estrogenic actions of ginsenoside Rg1 and estren in human breast cancer MCF-7 cells. J. Steroid Biochem. Mol. Biol. 2014, 141:104-112.
125. García M.A., Peña D., Alvarez L., Cocca C., Pontillo C., Bergoc R., de Pisarev D.K., Randi A. Hexachlorobenzene induces cell proliferation and IGF-I signaling pathway in an estrogen receptor alpha-dependent manner in MCF-7 breast cancer cell line. Toxicol. Lett. 2010, 192(2):195-205.
126. Garcia-Segura L.M., Diolez-Bojda F., Lenoir V., Naftolin F., Kerdelhué B. Estrogen-like effects of the mammary carcinogen 7,12-dimethylbenz(alpha)anthracene on hypothalamic neuronal membranes. Brain Res. Bull. 1992, 28(4):625-628.
127. Garritano S., Pinto B., Calderisi M., Cirillo T., Amodio-Cocchieri R., Reali D. Estrogen-like activity of seafood related to environmental chemical contaminants. Environ. Health 2006, 5:9.
128. Ghisari M., Bonefeld-Jorgensen E.C. Effects of plasticizers and their mixtures on estrogen receptor and thyroid hormone functions. Toxicol. Lett. 2009, 189(1):67-77.
129. Ghosh D., Taylor J.A., Green J.A., Lubahn D.B. Methoxychlor stimulates estrogen-responsive messenger ribonucleic acids in mouse uterus through a non-estrogen receptor (non-ER) alpha and non-ER beta mechanism. Endocrinology 1999, 140(8):3526-3533.
130. Gilad L.A., Schwartz B. Association of estrogen receptor beta with plasma-membrane caveola components: implication in control of vitamin D receptor. J. Mol. Endocrinol. 2007, 38(6):603-618.
131. Gilad L.A., Bresler T., Gnainsky J., Smirnoff P., Schwartz B. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J. Endocrinol. 2005, 185(3):577-592.
132. Gillies G.E., McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol. Rev. 2010, 62(2):155-198.
133. Giretti M.S., Montt Guevara M.M., Cecchi E., Mannella P., Palla G., Spina S., Bernacchi G., Di Bello S., Genazzani A.R., Genazzani A.D., Simoncini T. Effects of estetrol on migration and invasion in T47-D breast cancer cells through the actin cytoskeleton. Front. Endocrinol. (Lausanne) 2014, 5:80.
134. Go V., Garey J., Wolff M.S., Pogo B.G. Estrogenic potential of certain pyrethroid compounds in the MCF-7 human breast carcinoma cell line. Environ. Health Perspect. 1999, 107(3):173-177.
135. Goodin M.G., Fertuck K.C., Zacharewski T.R., Rosengren R.J. Estrogen receptor-mediated actions of polyphenolic catechins in vivo and in vitro. Toxicol. Sci. 2002, 69(2):354-361.
136. Gorodeski G.I. Role of nitric oxide and cyclic guanosine 3',5'-monophosphate in the estrogen regulation of cervical epithelial permeability. Endocrinology 2000, 141(5):1658-1666.
137. Gould J.C., Leonard L.S., Maness S.C., Wagner B.L., Conner K., Zacharewski T., Safe S., McDonnell D.P., Gaido K.W. Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol. Mol. Cell. Endocrinol. 1998, 142(1-2):203-214.
138. Gozgit J.M., Nestor K.M., Fasco M.J., Pentecost B.T., Arcaro K.F. Differential action of polycyclic aromatic hydrocarbons on endogenous estrogen-responsive genes and on a transfected estrogen-responsive reporter in MCF-7 cells. Toxicol. Appl. Pharmacol. 2004, 196(1):58-67.
139. Gräns J., Wassmur B., Celander M.C. One-way inhibiting cross-talk between arylhydrocarbon receptor (AhR) and estrogen receptor (ER) signaling in primary cultures of rainbow trout hepatocytes. Aquat. Toxicol. 2010, 100(3):263-270.
140. Grünfeld H.T., Bonefeld-Jorgensen E.C. Effect of in vitro estrogenic pesticides on human oestrogen receptor alpha and beta mRNA levels. Toxicol. Lett. 2004, 151(3):467-480.
141. Gunther J.R., Moore T.W., Collins M.L., Katzenellenbogen J.A. Amphipathic benzenes are designed inhibitors of the estrogen receptor alpha/steroid receptor coactivator interaction. ACS Chem. Biol. 2008, 3(5):282-286.
142. Guo D., Wang J., Wang X., Luo H., Zhang H., Cao D., Chen L., Huang N. Double directional adjusting estrogenic effect of naringin from Rhizoma drynariae (Gusuibu). J. Ethnopharmacol. 2011, 138(2):451-457.
143. Guo A.J., Choi R.C., Zheng K.Y., Chen V.P., Dong T.T., Wang Z.T., Vollmer G., Lau D.T., Tsim K.W. Kaempferol as a flavonoid induces osteoblastic differentiation via estrogen receptor signaling. Chin. Med. 2012, 7:10.
144. Hall J.M., Korach K.S. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol. Endocrinol. 2003, 17(5):792-803.
145. Hamblen E.L., Cronin M.T., Schultz T.W. Estrogenicity and acute toxicity of selected anilines using a recombinant yeast assay. Chemosphere 2003, 52(7):1173-1181.
146. Hamelers I.H., Van Schaik R.F., Sussenbach J.S., Steenbergh P.H. 17beta-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor. Cancer Cell Int. 2003, 3(1):10.
147. Han D.H., Denison M.S., Tachibana H., Yamada K. Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci. Biotechnol. Biochem. 2002, 66(7):1479-1487.
148. Han S.I., Komatsu Y., Murayama A., Steffensen K.R., Nakagawa Y., Nakajima Y., Suzuki M., Oie S., Parini P., Vedin L.L., Kishimoto H., Shimano H., Gustafsson J.Å., Yanagisawa J. Estrogen receptor ligands ameliorate fatty liver through a nonclassical estrogen receptor/Liver X receptor pathway in mice. Hepatology 2014, 59(5):1791-1802.
149. Hao R., Bondesson M., Singh A.V., Riu A., McCollum C.W., Knudsen T.B., Gorelick D.A., Gustafsson J.Å. Identification of estrogen target genes during zebrafish embryonic development through transcriptomic analysis. PLoS One 2013, 8(11):e79020.
150. Härkönen P.L., Väänänen H.K. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann. N. Y. Acad. Sci. 2006, 1089:218-227.
151. Harnagea-Theophilus E., Gadd S.L., Knight-Trent A.H., DeGeorge G.L., Miller M.R. Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors. Toxicol. Appl. Pharmacol. 1999, 155(3):273-279.
152. Harris C.A., Henttu P., Parker M.G., Sumpter J.P. The estrogenic activity of phthalate esters in vitro. Environ. Health Perspect. 1997, 105(8):802-811.
153. Harris D.M., Besselink E., Henning S.M., Go V.L., Heber D. Phytoestrogens induce differential estrogen receptor alpha- or beta-mediated responses in transfected breast cancer cells. Exp. Biol. Med. (Maywood) 2005, 230(8):558-568.
154. Hashimoto Y., Moriguchi Y., Oshima H., Nishikawa J., Nishihara T., Nakamura M. Estrogenic activity of chemicals for dental and similar use in vitro. J. Mater. Sci. Mater. Med. 2000, 11(8):465-468.
155. Hashimoto Y., Moriguchi Y., Oshima H., Kawaguchi M., Miyazaki K., Nakamura M. Measurement of estrogenic activity of chemicals for the development of new dental polymers. Toxicol. In Vitro 2001, 15(4-5):421-425.
156. Hashimoto Y., Kawaguchi M., Miyazaki K., Nakamura M. Estrogenic activity of tissue conditioners in vitro. Dent. Mater. 2003, 19(4):341-346.
157. Hashimoto R., Yu J., Koizumi H., Ouchi Y., Okabe T. Ginsenoside Rb1 prevents MPP(+)-induced apoptosis in PC12 cells by stimulating estrogen receptors with consequent activation of ERK1/2, Akt and inhibition of SAPK/JNK, p38 MAPK. Evid. Based Complement. Alternat. Med. 2012, 2012:693717.
158. Hattori Y., Kojima T., Kato D., Matsubara H., Takigawa M., Ishiguro N. A selective estrogen receptor modulator inhibits tumor necrosis factor-α-induced apoptosis through the ERK1/2 signaling pathway in human chondrocytes. Biochem. Biophys. Res. Commun. 2012, 421(3):418-424.
159. Hazell G.G., Yao S.T., Roper J.A., Prossnitz E.R., O'Carroll A.M., Lolait S.J. Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J. Endocrinol. 2009, 202(2):223-236.
160. Hegazy M.E., El-Hamd H., Mohamed A., El-Halawany A.M., Djemgou P.C., Shahat A.A., Paré P.W. Estrogenic activity of chemical constituents from Tephrosia candida. J. Nat. Prod. 2011, 74(5):937-942.
161. Henke B.R., Consler T.G., Go N., Hale R.L., Hohman D.R., Jones S.A., Lu A.T., Moore L.B., Moore J.T., Orband-Miller L.A., Robinett R.G., Shearin J., Spearing P.K., Stewart E.L., Turnbull P.S., Weaver S.L., Williams S.P., Wisely G.B., Lambert M.H. A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. J. Med. Chem. 2002, 45(25):5492-5505.
162. Hernández-Díaz F.J., Sánchez J.J., Abreu P., López-Coviella I., Tabares L., Prieto L., Alonso R. Estrogen modulates alpha(1)/beta-adrenoceptor-induced signaling and melatonin production in female rat pinealocytes. Neuroendocrinology 2001, 73(2):111-122.
163. Hien T.T., Kim N.D., Pokharel Y.R., Oh S.J., Lee M.Y., Kang K.W. Ginsenoside Rg3 increases nitric oxide production via increases in phosphorylation and expression of endothelial nitric oxide synthase: essential roles of estrogen receptor-dependent PI3-kinase and AMP-activated protein kinase. Toxicol. Appl. Pharmacol. 2010, 246(3):171-183.
164. Hien T.T., Oh W.K., Nguyen P.H., Oh S.J., Lee M.Y., Kang K.W. Nectandrin B activates endothelial nitric-oxide synthase phosphorylation in endothelial cells: role of the AMP-activated protein kinase/estrogen receptor α/phosphatidylinositol 3-kinase/Akt pathway. Mol. Pharmacol. 2011, 80(6):1166-1178.
165. Hirahara Y., Matsuda K.I., Liu Y.F., Yamada H., Kawata M., Boggs J.M. 17β-Estradiol and 17α-estradiol induce rapid changes in cytoskeletal organization in cultured oligodendrocytes. Neuroscience 2013, 235:187-199.
166. Hirsch K., Atzmon A., Danilenko M., Levy J., Sharoni Y. Lycopene and other carotenoids inhibit estrogenic activity of 17beta-estradiol and genistein in cancer cells. Breast Cancer Res. Treat. 2007, 104(2):221-230.
167. Hoekstra P.F., Burnison B.K., Garrison A.W., Neheli T., Muir D.C. Estrogenic activity of dicofol with the human estrogen receptor: isomer- and enantiomer-specific implications. Chemosphere 2006, 64(1):174-177.
168. Hong Y.H., Wang S.C., Hsu C., Lin B.F., Kuo Y.H., Huang C.J. Phytoestrogenic compounds in alfalfa sprout (Medicago sativa) beyond coumestrol. J. Agric. Food Chem. 2011, 59(1):131-137.
169. Houtman C.J., Van Oostveen A.M., Brouwer A., Lamoree M.H., Legler J. Identification of estrogenic compounds in fish bile using bioassay-directed fractionation. Environ. Sci. Technol. 2004, 38(23):6415-6423.
170. Howes M.J., Houghton P.J., Barlow D.J., Pocock V.J., Milligan S.R. Assessment of estrogenic activity in some common essential oil constituents. J. Pharm. Pharmacol. 2002, 54(11):1521-1528.
171. Hu J.Y., Aizawa T., Ookubo S. Products of aqueous chlorination of bisphenol A and their estrogenic activity. Environ. Sci. Technol. 2002, 36(9):1980-1987.
172. Huang Z., Fang F., Wang J., Wong C.W. Structural activity relationship of flavonoids with estrogen-related receptor gamma. FEBS Lett. 2010, 584(1):22-26.
173. Huang P.H., Huang C.Y., Chen M.C., Lee Y.T., Yue C.H., Wang H.Y., Lin H. Emodin and aloe-emodin suppress breast cancer cell proliferation through ER α inhibition. Evid. Based Complement. Alternat. Med. 2013, 2013:376123.
174. Hwang Y.P., Kim H.G., Hien T.T., Jeong M.H., Jeong T.C., Jeong H.G. Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase. Toxicol. Appl. Pharmacol. 2011, 257(1):48-58.
175. Hwang S.L., Lin J.A., Shih P.H., Yeh C.T., Yen G.C. Pro-cellular survival and neuroprotection of citrus flavonoid: the actions of hesperetin in PC12 cells. Food Funct. 2012, 3(10):1082-1090.
176. Hwang K.A., Park M.A., Kang N.H., Yi B.R., Hyun S.H., Jeung E.B., Choi K.C. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways. Toxicol. Appl. Pharmacol. 2013, 272(3):637-646.
177. Innocenti G., Vegeto E., Dall'Acqua S., Ciana P., Giorgetti M., Agradi E., Sozzi A., Fico G., Tomè F. In vitro estrogenic activity of Achillea millefolium L. Phytomedicine 2007, 14(2-3):147-152.
178. Ise R., Han D., Takahashi Y., Terasaka S., Inoue A., Tanji M., Kiyama R. Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. FEBS Lett. 2005, 579(7):1732-1740.
179. Ishibashi H., Ishida H., Matsuoka M., Tominaga N., Arizono K. Estrogenic effects of fluorotelomer alcohols for human estrogen receptor isoforms alpha and beta in vitro. Biol. Pharm. Bull. 2007, 30(7):1358-1359.
180. Ishikawa T., Yuhanna I.S., Umetani J., Lee W.R., Korach K.S., Shaul P.W., Umetani M. LXRβ/estrogen receptor-α signaling in lipid rafts preserves endothelial integrity. J. Clin. Invest. 2013, 123(8):3488-3497.
181. Isidori M., Bellotta M., Cangiano M., Parrella A. Estrogenic activity of pharmaceuticals in the aquatic environment. Environ. Int. 2009, 35(5):826-829.
182. Jang S.Y., Jang S.W., Ko J. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α. Cancer Lett. 2011, 300(1):57-65.
183. Jazin E.E., Dickerman H.W., Henrikson K.P. Estrogen regulation of a tissue factor-like procoagulant in the immature rat uterus. Endocrinology 1990, 126(1):176-185.
184. Ji Z.N., Zhao W.Y., Liao G.R., Choi R.C., Lo C.K., Dong T.T., Tsim K.W. In vitro estrogenic activity of formononetin by two bioassay systems. Gynecol. Endocrinol. 2006, 22(10):578-584.
185. Jiang S.Y., Shyu R.Y., Yeh M.Y., Jordan V.C. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J. Hepatol. 1995, 23(6):712-719.
186. Jiménez-Orozco F.A., Rosales A.A., Vega-López A., Domínguez-López M.L., García-Mondragón M.J., Maldonado-Espinoza A., Lemini C., Mendoza-Patiño N., Mandoki J.J. Differential effects of esculetin and daphnetin on in vitro cell proliferation and in vivo estrogenicity. Eur. J. Pharmacol. 2011, 668(1-2):35-41.
187. Jin J.S., Lee J.H., Hattori M. Ligand binding affinities of arctigenin and its demethylated metabolites to estrogen receptor alpha. Molecules 2013, 18(1):1122-1127.
188. Journe F., Laurent G., Chaboteaux C., Nonclercq D., Durbecq V., Larsimont D., Body J.J. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res. Treat. 2008, 107(1):49-61.
189. Jung J., Ishida K., Nishihara T. Anti-estrogenic activity of fifty chemicals evaluated by in vitro assays. Life Sci. 2004, 74(25):3065-3074.
190. Jung B.I., Kim M.S., Kim H.A., Kim D., Yang J., Her S., Song Y.S. Caffeic acid phenethyl ester, a component of beehive propolis, is a novel selective estrogen receptor modulator. Phytother. Res. 2010, 24(2):295-300.
191. Kajta M., Rzemieniec J., Litwa E., Lason W., Lenartowicz M., Krzeptowski W., Wojtowicz A.K. The key involvement of estrogen receptor β and G-protein-coupled receptor 30 in the neuroprotective action of daidzein. Neuroscience 2013, 238:345-360.
192. Kamiya M., Toriba A., Onoda Y., Kizu R., Hayakawa K. Evaluation of estrogenic activities of hydroxylated polycyclic aromatic hydrocarbons in cigarette smoke condensate. Food Chem. Toxicol. 2005, 43(7):1017-1027.
193. Kang L., Guo Y., Zhang X., Meng J., Wang Z.Y. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells. J. Steroid Biochem. Mol. Biol. 2011, 127(3-5):262-268.
194. Kang N.H., Hwang K.A., Lee H.R., Choi D.W., Choi K.C. Resveratrol regulates the cell viability promoted by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food Chem. Toxicol. 2013, 59:373-379.
195. Karpeta A., Ptak A., Gregoraszczuk E.L. Different action of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and its hydroxylated metabolites on ERα and ERβ gene and protein expression. Toxicol. Lett. 2014, 229(1):250-256.
196. Kashima H., Shiozawa T., Miyamoto T., Suzuki A., Uchikawa J., Kurai M., Konishi I. Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr. Relat. Cancer 2009, 16(1):113-122.
197. Kassem M., Okazaki R., Harris S.A., Spelsberg T.C., Conover C.A., Riggs B.L. Estrogen effects on insulin-like growth factor gene expression in a human osteoblastic cell line with high levels of estrogen receptor. Calcif. Tissue Int. 1998, 62(1):60-66.
198. Katzenellenbogen B.S. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. J. Soc. Gynecol. Investig. 2000, 7(1 Suppl.):S33-S37.
199. Kauss M.A., Reiterer G., Bunaciu R.P., Yen A. Human myeloblastic leukemia cells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp. Cell Res. 2008, 314(16):2999-3006.
200. Kavlock R.J., Daston G.P., DeRosa C., Fenner-Crisp P., Gray L.E., Kaattari S., Lucier G., Luster M., Mac M.J., Maczka C., Miller R., Moore J., Rolland R., Scott G., Sheehan D.M., Sinks T., Tilson H.A. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 1996, 104(Suppl. 4):715-740.
201. Kiefer T.L., Lai L., Yuan L., Dong C., Burow M.E., Hill S.M. Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins. J. Pineal Res. 2005, 38(4):231-239.
202. Kim S., Park T.I. Naringenin: a partial agonist on estrogen receptor in T47D-KBluc breast cancer cells. Int. J. Clin. Exp. Med. 2013, 6(10):890-899.
203. Kim S.S., Kwack S.J., Lee R.D., Lim K.J., Rhee G.S., Seok J.H., Kim B.H., Won Y.H., Lee G.S., Jeung E.B., Lee B.M., Park K.L. Assessment of estrogenic and androgenic activities of tetramethrin in vitro and in vivo assays. J. Toxicol. Environ. Health A 2005, 68(23-24):2277-2289.
204. Kim J.Y., Yi B.R., Go R.E., Hwang K.A., Nam K.H., Choi K.C. Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway. Environ. Toxicol. Pharmacol. 2014, 37(3):1264-1274.
205. Kirkegaard T., Hansen S.K., Larsen S.L., Reiter B.E., Sørensen B.S., Lykkesfeldt A.E. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014, 344(1):90-100.
206. Kirkiacharian S., Lormier A.T., Chidiack H., Bouchoux F., Cérède E. Synthesis and binding affinity to human alpha and beta estrogen receptors of various 7-hydroxycoumarins substituted at 4- and 3,4-positions. Farmaco 2004, 59(12):981-986.
207. Kiyama R., Zhu Y. DNA microarray-based gene expression profiling of estrogenic chemicals. Cell. Mol. Life Sci. 2014, 71(11):2065-2082.
208. Kiyama R., Zhu Y., Kawaguchi K., Iitake N., Wada-Kiyama Y., Dong S. Estrogen-responsive genes for environmental studies. Environ. Technol. Innov. 2014, 1-2:16-28.
209. Kjærstad M.B., Taxvig C., Nellemann C., Vinggaard A.M., Andersen H.R. Endocrine disrupting effects in vitro of conazole antifungals used as pesticides and pharmaceuticals. Reprod. Toxicol. 2010, 30(4):573-582.
210. Kjeldsen L.S., Bonefeld-Jørgensen E.C. Perfluorinated compounds affect the function of sex hormone receptors. Environ. Sci. Pollut. Res. Int. 2013, 20(11):8031-8044.
211. Kjeldsen L.S., Ghisari M., Bonefeld-Jørgensen E.C. Currently used pesticides and their mixtures affect the function of sex hormone receptors and aromatase enzyme activity. Toxicol. Appl. Pharmacol. 2013, 272(2):453-464.
212. Klann A., Levy G., Lutz I., Müller C., Kloas W., Hildebrandt J.P. Estrogen-like effects of ultraviolet screen 3-(4-methylbenzylidene)-camphor (Eusolex 6300) on cell proliferation and gene induction in mammalian and amphibian cells. Environ. Res. 2005, 97(3):274-281.
213. Klein-Hitpass L., Schorpp M., Wagner U., Ryffel G.U. An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 1986, 46(7):1053-1061.
214. Klinge C.M., Blankenship K.A., Risinger K.E., Bhatnagar S., Noisin E.L., Sumanasekera W.K., Zhao L., Brey D.M., Keynton R.S. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem. 2005, 280(9):7460-7468.
215. Klotz D.M., Beckman B.S., Hill S.M., McLachlan J.A., Walters M.R., Arnold S.F. Identification of environmental chemicals with estrogenic activity using a combination of in vitro assays. Environ. Health Perspect. 1996, 104(10):1084-1089.
216. Klotz D.M., Arnold S.F., McLachlan J.A. Inhibition of 17 beta-estradiol and progesterone activity in human breast and endometrial cancer cells by carbamate insecticides. Life Sci. 1997, 60(17):1467-1475.
217. Kohno Y., Kitamura S., Sanoh S., Sugihara K., Fujimoto N., Ohta S. Metabolism of the alpha, beta-unsaturated ketones, chalcone and trans-4-phenyl-3-buten-2-one, by rat liver microsomes and estrogenic activity of the metabolites. Drug Metab. Dispos. 2005, 33(8):1115-1123.
218. Kojima H., Katsura E., Takeuchi S., Niiyama K., Kobayashi K. Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ. Health Perspect. 2004, 112(5):524-531.
219. Kojima M., Fukunaga K., Sasaki M., Nakamura M., Tsuji M., Nishiyama T. Evaluation of estrogenic activities of pesticides using an in vitro reporter gene assay. Int. J. Environ. Health Res. 2005, 15(4):271-280.
220. Kojima H., Takeuchi S., Itoh T., Iida M., Kobayashi S., Yoshida T. In vitro endocrine disruption potential of organophosphate flame retardants via human nuclear receptors. Toxicology 2013, 314(1):76-83.
221. Kovalchuk S.N., Kozhemyako V.B., Atopkina L.N., Silchenko A.S., Avilov S.A., Kalinin V.I., Rasskazov V.A., Aminin D.L. Estrogenic activity of triterpene glycosides in yeast two-hybrid assay. J. Steroid Biochem. Mol. Biol. 2006, 101(4-5):226-231.
222. Krishnan V., Safe S. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships. Toxicol. Appl. Pharmacol. 1993, 120(1):55-61.
223. Krishnan V., Porter W., Santostefano M., Wang X., Safe S. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol. Cell. Biol. 1995, 15(12):6710-6719.
224. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., Gustafsson J.A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139(10):4252-4263.
225. Kummer V., Masková J., Zralý Z., Neca J., Simecková P., Vondrácek J., Machala M. Estrogenic activity of environmental polycyclic aromatic hydrocarbons in uterus of immature Wistar rats. Toxicol. Lett. 2008, 180(3):212-221.
226. Kung Sutherland M.S., Lipps S.G., Patnaik N., Gayo-Fung L.M., Khammungkune S., Xie W., Brady H.A., Barbosa M.S., Anderson D.W., Stein B. SP500263, a novel SERM, blocks osteoclastogenesis in a human bone cell model: role of IL-6 and GM-CSF. Cytokine 2003, 23(1-2):1-14.
227. Kurihara R., Shiraishi F., Tanaka N., Hashimoto S. Presence and estrogenicity of anthracene derivatives in coastal Japanese waters. Environ. Toxicol. Chem. 2005, 24(8):1984-1993.
228. Kuruto-Niwa R., Inoue S., Ogawa S., Muramatsu M., Nozawa R. Effects of tea catechins on the ERE-regulated estrogenic activity. J. Agric. Food Chem. 2000, 48(12):6355-6361.
229. La Rosa P., Pellegrini M., Totta P., Acconcia F., Marino M. Xenoestrogens alter estrogen receptor (ER) α intracellular levels. PLoS One 2014, 9(2):e88961.
230. Lappano R., Recchia A.G., De Francesco E.M., Angelone T., Cerra M.C., Picard D., Maggiolini M. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS One 2011, 6(1):e16631.
231. Laschke M.W., Schwender C., Scheuer C., Vollmar B., Menger M.D. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum. Reprod. 2008, 23(10):2308-2318.
232. Lee S.O., Nadiminty N., Wu X.X., Lou W., Dong Y., Ip C., Onate S.A., Gao A.C. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res. 2005, 65(8):3487-3492.
233. Lee H.S., Sasagawa S., Kato S., Fukuda R., Horiuchi H., Ohta A. Yeast two-hybrid detection systems that are highly sensitive to a certain kind of endocrine disruptors. Biosci. Biotechnol. Biochem. 2006, 70(2):521-524.
234. Lee H.J., Ju J., Paul S., So J.Y., DeCastro A., Smolarek A., Lee M.J., Yang C.S., Newmark H.L., Suh N. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin. Cancer Res. 2009, 15(12):4242-4249.
235. Lee S.A., Kim E.Y., Jeon W.K., Woo C.H., Choe J., Han S., Kim B.C. The inhibitory effect of raloxifene on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells is mediated through a ROS/p38 MAPK/CREB pathway to the up-regulation of heme oxygenase-1 independent of estrogen receptor. Biochimie 2011, 93(2):168-174.
236. Lee H.R., Hwang K.A., Park M.A., Yi B.R., Jeung E.B., Choi K.C. Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway. Int. J. Mol. Med. 2012, 29(5):883-890.
237. Lee H.R., Hwang K.A., Choi K.C. The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-β in the progression of LNCaP prostate cancer models. Int. J. Oncol. 2014, 45(2):595-602.
238. Lemaire G., Mnif W., Mauvais P., Balaguer P., Rahmani R. Activation of alpha- and beta-estrogen receptors by persistent pesticides in reporter cell lines. Life Sci. 2006, 79(12):1160-1169.
239. Leskinen P., Michelini E., Picard D., Karp M., Virta M. Bioluminescent yeast assays for detecting estrogenic and androgenic activity in different matrices. Chemosphere 2005, 61(2):259-266.
240. Letellier K., Azeddine B., Parent S., Labelle H., Rompré P.H., Moreau A., Moldovan F. Estrogen cross-talk with the melatonin signaling pathway in human osteoblasts derived from adolescent idiopathic scoliosis patients. J. Pineal Res. 2008, 45(4):383-393.
241. Leung K.W., Leung F.P., Mak N.K., Tombran-Tink J., Huang Y., Wong R.N. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells. Br. J. Pharmacol. 2009, 156(4):626-637.
242. Lewis-Wambi J.S., Jordan V.C. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?. Breast Cancer Res. 2009, 11(3):206.
243. Li J., Gramatica P. The importance of molecular structures, endpoints' values, and predictivity parameters in QSAR research: QSAR analysis of a series of estrogen receptor binders. Mol. Divers. 2010, 14(4):687-696.
244. Li C., Taneda S., Suzuki A.K., Furuta C., Watanabe G., Taya K. Estrogenic and anti-androgenic activities of 4-nitrophenol in diesel exhaust particles. Toxicol. Appl. Pharmacol. 2006, 217(1):1-6.
245. Li Y., Yuan Y.Y., Meeran S.M., Tollefsbol T.O. Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol. Cancer 2010, 9:274.
246. Li J., Ma M., Wang Z. In vitro profiling of endocrine disrupting effects of phenols. Toxicol. In Vitro 2010, 24(1):201-207.
247. Li Y., Burns K.A., Arao Y., Luh C.J., Korach K.S. Differential estrogenic actions of endocrine-disrupting chemicals bisphenol A, bisphenol AF, and zearalenone through estrogen receptor α and β in vitro. Environ. Health Perspect. 2012, 120(7):1029-1035.
248. Li Y.C., Ding X.S., Li H.M., Zhang C. Icariin attenuates high glucose-induced type IV collagen and fibronectin accumulation in glomerular mesangial cells by inhibiting transforming growth factor-β production and signalling through G protein-coupled oestrogen receptor 1. Clin. Exp. Pharmacol. Physiol. 2013, 40(9):635-643.
249. Li X., Gao Y., Guo L.H., Jiang G. Structure-dependent activities of hydroxylated polybrominated diphenyl ethers on human estrogen receptor. Toxicology 2013, 309:15-22.
250. Li Q., Sullivan N.R., McAllister C.E., Van de Kar L.D., Muma N.A. Estradiol accelerates the effects of fluoxetine on serotonin 1A receptor signaling. Psychoneuroendocrinology 2013, 38(7):1145-1157.
251. Li X., Ye L., Wang X., Shi W., Qian X., Zhu Y., Yu H. Molecular modeling and molecular dynamics simulation studies on the interactions of hydroxylated polychlorinated biphenyls with estrogen receptor-β. Arch. Environ. Contam. Toxicol. 2013, 65(3):357-367.
252. Li Y.C., Ding X.S., Li H.M., Zhang Y., Bao J. Role of G protein-coupled estrogen receptor 1 in modulating transforming growth factor-β stimulated mesangial cell extracellular matrix synthesis and migration. Mol. Cell. Endocrinol. 2014, 391(1-2):50-59.
253. Li J., Wang F., Ding H., Jin C., Chen J., Zhao Y., Li X., Chen W., Sun P., Tan Y., Zhang Q., Wang X., Fan A., Hua Q. Geniposide, the component of the Chinese herbal formula Tongluojiunao, protects amyloid-β peptide (1-42-mediated death of hippocampal neurons via the non-classical estrogen signaling pathway. Neural Regen. Res. 2014, 9(5):474-480.
254. Liao M.H., Tai Y.T., Cherng Y.G., Liu S.H., Chang Y.A., Lin P.I., Chen R.M. Genistein induces oestrogen receptor-α gene expression in osteoblasts through the activation of mitogen-activated protein kinases/NF-κB/activator protein-1 and promotes cell mineralisation. Br. J. Nutr. 2014, 111(1):55-63.
255. Lim S.H., Ha T.Y., Ahn J., Kim S. Estrogenic activities of Psoralea corylifolia L. seed extracts and main constituents. Phytomedicine 2011, 18(5):425-430.
256. Lin C.W., Yang L.Y., Shen S.C., Chen Y.C. IGF-I plus E2 induces proliferation via activation of ROS-dependent ERKs and JNKs in human breast carcinoma cells. J. Cell. Physiol. 2007, 212(3):666-674.
257. Lin S.L., Yan L.Y., Liang X.W., Wang Z.B., Wang Z.Y., Qiao J., Schatten H., Sun Q.Y. A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod. Biol. Endocrinol. 2009, 7:102.
258. Liu S., Sugimoto Y., Kulp S.K., Jiang J., Chang H.L., Park K.Y., Kashida Y., Lin Y.C. Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. Anticancer Res. 2002, 22(6C):3917-3923.
259. Liu S., Abdelrahim M., Khan S., Ariazi E., Jordan V.C., Safe S. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol. Chem. 2006, 387(9):1209-1213.
260. Liu J., Li J., Sidell N. Modulation by phenylacetate of early estrogen-mediated events in MCF-7 breast cancer cells. Cancer Chemother. Pharmacol. 2007, 59(2):217-225.
261. Liu T., Jin H., Sun Q.R., Xu J.H., Hu H.T. Neuroprotective effects of emodin in rat cortical neurons against beta-amyloid-induced neurotoxicity. Brain Res. 2010, 1347:149-160.
262. Liu H., Du J., Hu C., Qi H., Wang X., Wang S., Liu Q., Li Z. Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells. J. Nutr. Biochem. 2010, 21(5):390-396.
263. Liu X., Nam J.W., Song Y.S., Viswanath A.N., Pae A.N., Kil Y.S., Kim H.D., Park J.H., Seo E.K., Chang M. Psoralidin, a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia. Bioorg. Med. Chem. Lett. 2014, 24(5):1403-1406.
264. Lopes Costa A., Le Bachelier C., Mathieu L., Rotig A., Boneh A., De Lonlay P., Tarnopolsky M.A., Thorburn D.R., Bastin J., Djouadi F. Beneficial effects of resveratrol on respiratory chain defects in patients' fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling. Hum. Mol. Genet. 2014, 23(8):2106-2119.
265. Lou Q.Q., Zhang Y.F., Zhou Z., Shi Y.L., Ge Y.N., Ren D.K., Xu H.M., Zhao Y.X., Wei W.J., Qin Z.F. Effects of perfluorooctanesulfonate and perfluorobutanesulfonate on the growth and sexual development of Xenopus laevis. Ecotoxicology 2013, 22(7):1133-1144.
266. Luo W., Friedman M.S., Shedden K., Hankenson K.D., Woolf P.J. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinforma. 2009, 10:161.
267. Luo L.J., Liu F., Lin Z.K., Xie Y.F., Xu J.L., Tong Q.C., Shu R. Genistein regulates the IL-1 beta induced activation of MAPKs in human periodontal ligament cells through G protein-coupled receptor 30. Arch. Biochem. Biophys. 2012, 522(1):9-16.
268. Ma H.R., Wang J., Chen Y.F., Chen H., Wang W.S., Aisa H.A. Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway. Int. J. Mol. Med. 2014, 33(6):1627-1634.
269. Machala M., Ciganek M., Bláha L., Minksová K., Vondráck J. Aryl hydrocarbon receptor-mediated and estrogenic activities of oxygenated polycyclic aromatic hydrocarbons and azaarenes originally identified in extracts of river sediments. Environ. Toxicol. Chem. 2001, 20(12):2736-2743.
270. Machida K., Abe T., Arai D., Okamoto M., Shimizu I., de Voogd N.J., Fusetani N., Nakao Y. Cinanthrenol A, an estrogenic steroid containing phenanthrene nucleus, from a marine sponge Cinachyrella sp. Org. Lett. 2014, 16(6):1539-1541.
271. Maggiolini M., Statti G., Vivacqua A., Gabriele S., Rago V., Loizzo M., Menichini F., Amdò S. Estrogenic and antiproliferative activities of isoliquiritigenin in MCF7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 2002, 82(4-5):315-322.
272. Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., Montanaro D., Musti A.M., Picard D., Andò S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 2004, 279(26):27008-27016.
273. Maggiolini M., Recchia A.G., Bonofiglio D., Catalano S., Vivacqua A., Carpino A., Rago V., Rossi R., Andò S. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells. J. Mol. Endocrinol. 2005, 35(2):269-281.
274. Mahmoodzadeh S., Fritschka S., Dworatzek E., Pham T.H., Becher E., Kuehne A., Davidson M.M., Regitz-Zagrosek V. Nuclear factor-kappaB regulates estrogen receptor-alpha transcription in the human heart. J. Biol. Chem. 2009, 284(37):24705-24714.
275. Mahmoodzadeh S., Leber J., Zhang X., Jaisser F., Messaoudi S., Morano I., Furth P.A., Dworatzek E., Regitz-Zagrosek V. Cardiomyocyte-specific estrogen receptor alpha increases angiogenesis, lymphangiogenesis and reduces fibrosis in the female mouse heart post-myocardial infarction. J. Cell Sci. Ther. 2014, 5(1):153.
276. Mak P., Leung Y.K., Tang W.Y., Harwood C., Ho S.M. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 2006, 8(11):896-904.
277. Manabe M., Kanda S., Fukunaga K., Tsubura A., Nishiyama T. Evaluation of the estrogenic activities of some pesticides and their combinations using MtT/Se cell proliferation assay. Int. J. Hyg. Environ. Health 2006, 209(5):413-421.
278. Mandal A., Bhatia D., Bishayee A. Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats. Mol. Cell. Biochem. 2013, 384(1-2):239-250.
279. Mann V., Huber C., Kogianni G., Collins F., Noble B. The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone 2007, 40(3):674-684.
280. Maranghi F., Tassinari R., Marcoccia D., Altieri I., Catone T., De Angelis G., Testai E., Mastrangelo S., Evandri M.G., Bolle P., Lorenzetti S. The food contaminant semicarbazide acts as an endocrine disrupter: evidence from an integrated in vivo/in vitro approach. Chem. Biol. Interact. 2010, 183(1):40-48.
281. Maras M., Vanparys C., Muylle F., Robbens J., Berger U., Barber J.L., Blust R., De Coen W. Estrogen-like properties of fluorotelomer alcohols as revealed by mcf-7 breast cancer cell proliferation. Environ. Health Perspect. 2006, 114(1):100-105.
282. Marconett C.N., Singhal A.K., Sundar S.N., Firestone G.L. Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol. Cell. Endocrinol. 2012, 363(1-2):74-84.
283. Marino M., Pellegrini M., La Rosa P., Acconcia F. Susceptibility of estrogen receptor rapid responses to xenoestrogens: physiological outcomes. Steroids 2012, 77(10):910-917.
284. Martin M.B., Reiter R., Pham T., Avellanet Y.R., Camara J., Lahm M., Pentecost E., Pratap K., Gilmore B.A., Divekar S., Dagata R.S., Bull J.L., Stoica A. Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology 2003, 144(6):2425-2436.
285. Matsuda H., Shimoda H., Morikawa T., Yoshikawa M. Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity. Bioorg. Med. Chem. Lett. 2001, 11(14):1839-1842.
286. Maximov P.Y., Lee T.M., Jordan V.C. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr. Clin. Pharmacol. 2013, 8(2):135-155.
287. McAllister C.E., Creech R.D., Kimball P.A., Muma N.A., Li Q. GPR30 is necessary for estradiol-induced desensitization of 5-HT1A receptor signaling in the paraventricular nucleus of the rat hypothalamus. Psychoneuroendocrinology 2012, 37(8):1248-1260.
288. McCarthy A.R., Thomson B.M., Shaw I.C., Abell A.D. Estrogenicity of pyrethroid insecticide metabolites. J. Environ. Monit. 2006, 8(1):197-202.
289. McLachlan M.J., Katzenellenbogen J.A., Zhao H. A new fluorescence complementation biosensor for detection of estrogenic compounds. Biotechnol. Bioeng. 2011, 108(12):2794-2803.
290. McPherson S.J., Ellem S.J., Risbridger G.P. Estrogen-regulated development and differentiation of the prostate. Differentiation 2008, 76(6):660-670.
291. Medjakovic S., Jungbauer A. Red clover isoflavones biochanin A and formononetin are potent ligands of the human aryl hydrocarbon receptor. J. Steroid Biochem. Mol. Biol. 2008, 108(1-2):171-177.
292. Medjakovic S., Zoechling A., Gerster P., Ivanova M.M., Teng Y., Klinge C.M., Schildberger B., Gartner M., Jungbauer A. Effect of nonpersistent pesticides on estrogen receptor, androgen receptor, and aryl hydrocarbon receptor. Environ. Toxicol. 2014, 29(10):1201-1216.
293. Meerts I.A., Letcher R.J., Hoving S., Marsh G., Bergman A., Lemmen J.G., van der Burg B., Brouwer A. In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds. Environ. Health Perspect. 2001, 109(4):399-407.
294. Mellanen P., Petänen T., Lehtimäki J., Mäkelä S., Bylund G., Holmbom B., Mannila E., Oikari A., Santti R. Wood-derived estrogens: studies in vitro with breast cancer cell lines and in vivo in trout. Toxicol. Appl. Pharmacol. 1996, 136(2):381-388.
295. Menendez J.A., Colomer R., Lupu R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cells. Int. J. Cancer 2004, 109(6):949-954.
296. Meng R., Tang H.Y., Westfall J., London D., Cao J.H., Mousa S.A., Luidens M., Hercbergs A., Davis F.B., Davis P.J., Lin H.Y. Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One 2011, 6(11):e27547.
297. Meng X., Sun G., Ye J., Xu H., Wang H., Sun X. Notoginsenoside R1-mediated neuroprotection involves estrogen receptor-dependent crosstalk between Akt and ERK1/2 pathways: a novel mechanism of Nrf2/ARE signaling activation. Free Radic. Res. 2014, 48(4):445-460.
298. Mense S.M., Singh B., Remotti F., Liu X., Bhat H.K. Vitamin C and alpha-naphthoflavone prevent estrogen-induced mammary tumors and decrease oxidative stress in female ACI rats. Carcinogenesis 2009, 30(7):1202-1208.
299. Mercado-Feliciano M., Bigsby R.M. Hydroxylated metabolites of the polybrominated diphenyl ether mixture DE-71 are weak estrogen receptor-alpha ligands. Environ. Health Perspect. 2008, 116(10):1315-1321.
300. Mersereau J.E., Levy N., Staub R.E., Baggett S., Zogovic T., Chow S., Ricke W.A., Tagliaferri M., Cohen I., Bjeldanes L.F., Leitman D.C. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol. Cell. Endocrinol. 2008, 283(1-2):49-57.
301. Métivier R., Penot G., Flouriot G., Pakdel F. Synergism between ERalpha transactivation function 1 (AF-1) and AF-2 mediated by steroid receptor coactivator protein-1: requirement for the AF-1 alpha-helical core and for a direct interaction between the N- and C-terminal domains. Mol. Endocrinol. 2001, 15(11):1953-1970.
302. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 2001, 44(24):4230-4251.
303. Micevych P.E., Kelly M.J. Membrane estrogen receptor regulation of hypothalamic function. Neuroendocrinology 2012, 96(2):103-110.
304. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., Gong W., Beato M., Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998, 17(7):2008-2018.
305. Migliaccio A., Castoria G., Di Domenico M., Ciociola A., Lombardi M., De Falco A., Nanayakkara M., Bottero D., De Stasio R., Varricchio L., Auricchio F. Crosstalk between EGFR and extranuclear steroid receptors. Ann. N. Y. Acad. Sci. 2006, 1089:194-200.
306. Min G. Estrogen modulates transactivations of SXR-mediated liver×receptor response element and CAR-mediated phenobarbital response element in HepG2 cells. Exp. Mol. Med. 2010, 42(11):731-738.
307. Min G., Kim H., Bae Y., Petz L., Kemper J.K. Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. J. Biol. Chem. 2002, 277(37):34626-34633.
308. Misiewicz B., Griebler C., Gomez M., Raybourne R., Zelazowska E., Gold P.W., Sternberg E.M. The estrogen antagonist tamoxifen inhibits carrageenan induced inflammation in LEW/N female rats. Life Sci. 1996, 58(16):L281-L286.
309. Moggs J.G., Orphanides G. Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep. 2001, 2(9):775-781.
310. Morrissey C., Bektic J., Spengler B., Galvin D., Christoffel V., Klocker H., Fitzpatrick J.M., Watson R.W. Phytoestrogens derived from Belamcanda chinensis have an antiproliferative effect on prostate cancer cells in vitro. J. Urol. 2004, 172(6 Pt 1):2426-2433.
311. Mortensen A.S., Arukwe A. Estrogenic effect of dioxin-like aryl hydrocarbon receptor (AhR) agonist (PCB congener 126) in salmon hepatocytes. Mar. Environ. Res. 2008, 66(1):119-120.
312. Muchekehu R.W., Harvey B.J. 17Beta-estradiol rapidly mobilizes intracellular calcium from ryanodine-receptor-gated stores via a PKC-PKA-Erk-dependent pathway in the human eccrine sweat gland cell line NCL-SG3. Cell Calcium 2008, 44(3):276-288.
313. Mueller S.O. Xenoestrogens: mechanisms of action and detection methods. Anal. Bioanal. Chem. 2004, 378(3):582-587.
314. Müller J.C., Imazaki P.H., Boareto A.C., Lourenço E.L., Golin M., Vechi M.F., Lombardi N.F., Minatovicz B.C., Scippo M.L., Martino-Andrade A.J., Dalsenter P.R. In vivo and in vitro estrogenic activity of the antidepressant fluoxetine. Reprod. Toxicol. 2012, 34(1):80-85.
315. Nadal A., Rovira J.M., Laribi O., Leon-quinto T., Andreu E., Ripoll C., Soria B. Rapid insulinotropic effect of 17beta-estradiol via a plasma membrane receptor. FASEB J. 1998, 12(13):1341-1348.
316. Nadzialek S., Depiereux S., Mandiki S.N., Kestemont P. In vivo biomarkers of estrogenicity: limitation of interpretation in wild environment. Arch. Environ. Contam. Toxicol. 2011, 60(3):471-478.
317. Nakaya M., Tachibana H., Yamada K. Isoflavone genistein and daidzein up-regulate LPS-induced inducible nitric oxide synthase activity through estrogen receptor pathway in RAW264.7 cells. Biochem. Pharmacol. 2005, 71(1-2):108-114.
318. Nakaya Y., Mawatari K., Takahashi A., Harada N., Hata A., Yasui S. The phytoestrogen ginsensoside Re activates potassium channels of vascular smooth muscle cells through PI3K/Akt and nitric oxide pathways. J. Med. Invest. 2007, 54(3-4):381-384.
319. Namgoong G.M., Khanal P., Cho H.G., Lim S.C., Oh Y.K., Kang B.S., Shim J.H., Yoo J.C., Choi H.S. The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J. Biol. Chem. 2010, 285(31):23829-23841.
320. National Research Council (US) Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, National Academies Press (US), Washington, DC.
321. National Research Council (US) Toxicity-Pathway-Based Risk Assessment: Preparing for Paradigm Change: A Symposium Summary 2010, National Academies Press (US), Washington, DC.
322. Ndebele K., Graham B., Tchounwou P.B. Estrogenic activity of coumestrol, DDT, and TCDD in human cervical cancer cells. Int. J. Environ. Res. Public Health 2010, 7(5):2045-2056.
323. Nejati-Koshki K., Zarghami N., Pourhassan-Moghaddam M., Rahmati-Yamchi M., Mollazade M., Nasiri M., Esfahlan R.J., Barkhordari A., Tayefi-Nasrabadi H. Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology 2012, 64(6):719-726.
324. Nethrapalli I.S., Tinnikov A.A., Krishnan V., Lei C.D., Toran-Allerand C.D. Estrogen activates mitogen-activated protein kinase in native, nontransfected CHO-K1, COS-7, and RAT2 fibroblast cell lines. Endocrinology 2005, 146(1):56-63.
325. Nilsson S., Mäkelä S., Treuter E., Tujague M., Thomsen J., Andersson G., Enmark E., Pettersson K., Warner M., Gustafsson J.A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81(4):1535-1565.
326. Nishiguchi T., Kobayashi T., Sugimura M., Kobayashi H., Terao T. Upregulation of thrombomodulin antigen levels in U937 cells by combined stimulation with estradiol-17beta and vitamin K2 (menaquinone 4). Semin. Thromb. Hemost. 1999, 25(5):509-517.
327. Nishikawa J., Saito K., Goto J., Dakeyama F., Matsuo M., Nishihara T. New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator. Toxicol. Appl. Pharmacol. 1999, 154(1):76-83.
328. Nishimura S., Taki M., Takaishi S., Iijima Y., Akiyama T. Structures of 4-aryl-coumarin (neoflavone) dimers isolated from Pistacia chinensis BUNGE and their estrogen-like activity. Chem. Pharm. Bull. (Tokyo) 2000, 48(4):505-508.
329. Nishizuka M., Heitaku S., Maekawa S., Nishikawa j, Imagawa M. Development of standardized in vitro assay system for estrogen receptors and species specificity of binding ability of 4-nonylphenol and p-octylphenol. J. Health Sci. 2004, 50(5):511-517.
330. Novensa L., Selent J., Pastor M., Sandberg K., Heras M., Dantas A.P. Equine estrogens impair nitric oxide production and endothelial nitric oxide synthase transcription in human endothelial cells compared with the natural 17β-estradiol. Hypertension 2010, 56(3):405-411.
331. Nwachukwu J.C., Srinivasan S., Bruno N.E., Parent A.A., Hughes T.S., Pollock J.A., Gjyshi O., Cavett V., Nowak J., Garcia-Ordonez R.D., Houtman R., Griffin P.R., Kojetin D.J., Katzenellenbogen J.A., Conkright M.D., Nettles K.W. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. Elife 2014, 3:e02057.
332. Obrero M., Yu D.V., Shapiro D.J. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J. Biol. Chem. 2002, 277(47):45695-45703.
333. Oda K., Nishimura T., Higuchi K., Ishido N., Ochi K., Iizasa H., Sai Y., Tomi M., Nakashima E. Estrogen receptor α induction by mitoxantrone increases Abcg2 expression in placental trophoblast cells. J. Pharm. Sci. 2013, 102(9):3364-3372.
334. Oh S.M., Chung K.H. Estrogenic activities of Ginkgo biloba extracts. Life Sci. 2004, 74(11):1325-1335.
335. Oh Y.J., Jung Y.J., Kang J.W., Yoo Y.S. Investigation of the estrogenic activities of pesticides from Pal-dang reservoir by in vitro assay. Sci. Total Environ. 2007, 388(1-3):8-15.
336. Ohta K., Chiba Y., Ogawa T., Endo Y. Promising core structure for nuclear receptor ligands: design and synthesis of novel estrogen receptor ligands based on diphenylamine skeleton. Bioorg. Med. Chem. Lett. 2008, 18(18):5050-5053.
337. Ohta R., Takagi A., Ohmukai H., Marumo H., Ono A., Matsushima Y., Inoue T., Ono H., Kanno J. Ovariectomized mouse uterotrophic assay of 36 chemicals. J. Toxicol. Sci. 2012, 37(5):879-889.
338. Ohta K., Ogawa T., Kaise A., Endo Y. Novel estrogen receptor (ER) modulators containing various hydrophobic bent-core structures. Bioorg. Med. Chem. 2014, 22(13):3508-3514.
339. Ohtani-Kaneko R. Mechanisms underlying estrogen-induced sexual differentiation in the hypothalamus. Histol. Histopathol. 2006, 21(3):317-324.
340. Oishi K., Toyao K., Kawano Y. Suppression of estrogenic activity of 17-beta-estradiol by beta-cyclodextrin. Chemosphere 2008, 73(11):1788-1792.
341. Okubo T., Yokoyama Y., Kano K., Soya Y., Kano I. Estimation of estrogenic and antiestrogenic activities of selected pesticides by MCF-7 cell proliferation assay. Arch. Environ. Contam. Toxicol. 2004, 46(4):445-453.
342. Olsen C.M., Meussen-Elholm E.T., Samuelsen M., Holme J.A., Hongslo J.K. Effects of the environmental oestrogens bisphenol A, tetrachlorobisphenol A, tetrabromobisphenol A, 4-hydroxybiphenyl and 4,'4'-dihydroxybiphenyl on oestrogen receptor binding, cell proliferation and regulation of oestrogen sensitive proteins in the human breast cancer cell line MCF-7. Pharmacol. Toxicol. 2003, 92(4):180-188.
343. Ombra M.N., Di Santi A., Abbondanza C., Migliaccio A., Avvedimento E.V., Perillo B. Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochim. Biophys. Acta 2013, 1829(5):480-486.
344. Ong E.T., Hwang T.L., Huang Y.L., Lin C.F., Wu W.B. Vitisin B, a resveratrol tetramer, inhibits migration through inhibition of PDGF signaling and enhancement of cell adhesiveness in cultured vascular smooth muscle cells. Toxicol. Appl. Pharmacol. 2011, 256(2):198-208.
345. Ono M., Yin P., Navarro A., Moravek M.B., Coon J.S., Druschitz S.A., Serna V.A., Qiang W., Brooks D.C., Malpani S.S., Ma J., Ercan C.M., Mittal N., Monsivais D., Dyson M.T., Yemelyanov A., Maruyama T., Chakravarti D., Kim J.J., Kurita T., Gottardi C.J., Bulun S.E. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(42):17053-17058.
346. Onorato J., Henion J.D. Evaluation of triterpene glycoside estrogenic activity using LC/MS and immunoaffinity extraction. Anal. Chem. 2001, 73(19):4704-4710.
347. Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. 2005, 11(2 Pt 2):865s-870s.
348. Palmieri D., Perego P., Palombo D. Estrogen receptor activation protects against TNF-α-induced endothelial dysfunction. Angiology 2014, 65(1):17-21.
349. Pang W.Y., Wang X.L., Mok S.K., Lai W.P., Chow H.K., Leung P.C., Yao X.S., Wong M.S. Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. Br. J. Pharmacol. 2010, 159(8):1693-1703.
350. Panno M.L., Giordano F., Rizza P., Pellegrino M., Zito D., Giordano C., Mauro L., Catalano S., Aquila S., Sisci D., De Amicis F., Vivacqua A., Fuqua S.W., Andò S. Bergapten induces ER depletion in breast cancer cells through SMAD4-mediated ubiquitination. Breast Cancer Res. Treat. 2012, 136(2):443-455.
351. Papoutsi Z., Kassi E., Mitakou S., Aligiannis N., Tsiapara A., Chrousos G.P., Moutsatsou P. Acteoside and martynoside exhibit estrogenic/antiestrogenic properties. J. Steroid Biochem. Mol. Biol. 2006, 98(1):63-71.
352. Park S.H., Kim K.Y., An B.S., Choi J.H., Jeung E.B., Leung P.C., Choi K.C. Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. J. Reprod. Dev. 2009, 55(1):23-29.
353. Park S.B., Bae J.W., Kim J.M., Lee S.G., Han M. Antiproliferative and apoptotic effect of epigallocatechin-3-gallate on Ishikawa cells is accompanied by sex steroid receptor downregulation. Int. J. Mol. Med. 2012, 30(5):1211-1218.
354. Parker M.G. Transcriptional activation by oestrogen receptors. Biochem. Soc. Symp. 1998, 63:45-50.
355. Parveen M., Inoue A., Ise R., Tanji M., Kiyama R. Evaluation of estrogenic activity of phthalate esters by gene expression profiling using a focused microarray (EstrArray). Environ. Toxicol. Chem. 2008, 27(6):1416-1425.
356. Pazaiti A., Kontos M., Fentiman I.S. ZEN and the art of breast health maintenance. Int. J. Clin. Pract. 2012, 66(1):28-36.
357. Pearl C.A., Mason H., Roser J.F. Immunolocalization of estrogen receptor alpha, estrogen receptor beta and androgen receptor in the pre-, peri- and post-pubertal stallion testis. Anim. Reprod. Sci. 2011, 125(1-4):103-111.
358. Penttinen P., Jaehrling J., Damdimopoulos A.E., Inzunza J., Lemmen J.G., van der Saag P., Pettersson K., Gauglitz G., Mäkelä S., Pongratz I. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 2007, 148(10):4875-4886.
359. Petit F., Le Goff P., Cravédi J.P., Valotaire Y., Pakdel F. Two complementary bioassays for screening the estrogenic potency of xenobiotics: recombinant yeast for trout estrogen receptor and trout hepatocyte cultures. J. Mol. Endocrinol. 1997, 19(3):321-335.
360. Pianjing P., Thiantanawat A., Rangkadilok N., Watcharasit P., Mahidol C., Satayavivad J. Estrogenic activities of sesame lignans and their metabolites on human breast cancer cells. J. Agric. Food Chem. 2011, 59(1):212-221.
361. Picard K., Lhuguenot J.C., Lavier-Canivenc M.C., Chagnon M.C. Estrogenic activity and metabolism of n-butyl benzyl phthalate in vitro: identification of the active molecule(s). Toxicol. Appl. Pharmacol. 2001, 172(2):108-118.
362. Piccolella M., Crippa V., Messi E., Tetel M.J., Poletti A. Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells. Pharmacol. Res. 2014, 79:13-20.
363. Plísková M., Vondrácek J., Kren V., Gazák R., Sedmera P., Walterová D., Psotová J., Simánek V., Machala M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 2005, 215(1-2):80-89.
364. Plotan M., Elliott C.T., Oplatowska M., Connolly L. Validation and application of reporter gene assays for the determination of estrogenic and androgenic endocrine disruptor activity in sport supplements. Anal. Bioanal. Chem. 2012, 403(10):3057-3067.
365. Pons M., Gagne D., Nicolas J.C., Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 1990, 9(4):450-459.
366. Prakash P., Russell R.M., Krinsky N.I. In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. J. Nutr. 2001, 131(5):1574-1580.
367. Prifti S., Mall P., Rabe T. Synthetic estrogen-mediated activation of ERK 2 intracellular signaling molecule. Gynecol. Endocrinol. 2003, 17(5):423-428.
368. Ptak A., Ludewig G., Gregoraszczuk E.Ł. A low halogenated biphenyl (PCB3) increases CYP1A1 expression and activity via the estrogen receptor beta in the porcine ovary. J. Physiol. Pharmacol. 2008, 59(3):577-588.
369. Qu J., Liu W., Huang C., Xu C., Du G., Gu A., Wang X. Estrogen receptors are involved in polychlorinated biphenyl-induced apoptosis on mouse spermatocyte GC-2 cell line. Toxicol. In Vitro 2014, 28(3):373-380.
370. Radice S., Chiesara E., Frigerio S., Fumagalli R., Parolaro D., Rubino T., Marabini L. Estrogenic effect of procymidone through activation of MAPK in MCF-7 breast carcinoma cell line. Life Sci. 2006, 78(23):2716-2723.
371. Rafi M.M., Rosen R.T., Vassil A., Ho C.T., Zhang H., Ghai G., Lambert G., DiPaola R.S. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res. 2000, 20(4):2653-2658.
372. Rahal O.M., Simmen R.C. Paracrine-acting adiponectin promotes mammary epithelial differentiation and synergizes with genistein to enhance transcriptional response to estrogen receptor β signaling. Endocrinology 2011, 152(9):3409-3421.
373. Randall C., et al. National Pesticide Applicator Certification Core Manual 2013, National Association of State Departments of Agriculture Research Foundation, Washington, DC.
374. Rao J., Jiang X., Wang Y., Chen B. Advances in the understanding of the structure and function of ER-α36, a novel variant of human estrogen receptor-alpha. J. Steroid Biochem. Mol. Biol. 2011, 127(3-5):231-237.
375. Renoir J.M., Marsaud V., Lazennec G. Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem. Pharmacol. 2013, 85(4):449-465.
376. Resende F.A., de Oliveira A.P., de Camargo M.S., Vilegas W., Varanda E.A. Evaluation of estrogenic potential of flavonoids using a recombinant yeast strain and MCF7/BUS cell proliferation assay. PLoS One 2013, 8(10):e74881.
377. Ribeiro J.R., Freiman R.N. Estrogen signaling crosstalk: implications for endocrine resistance in ovarian cancer. J. Steroid Biochem. Mol. Biol. 2014, 143:160-173.
378. Riby J.E., Feng C., Chang Y.C., Schaldach C.M., Firestone G.L., Bjeldanes L.F. The major cyclic trimeric product of indole-3-carbinol is a strong agonist of the estrogen receptor signaling pathway. Biochemistry 2000, 39(5):910-918.
379. Riverso M., Kortenkamp A., Silva E. Non-tumorigenic epithelial cells secrete MCP-1 and other cytokines that promote cell division in breast cancer cells by activating ERα via PI3K/Akt/mTOR signaling. Int. J. Biochem. Cell Biol. 2014, 53C:281-294.
380. Robb E.L., Stuart J.A. The stilbenes resveratrol, pterostilbene and piceid affect growth and stress resistance in mammalian cells via a mechanism requiring estrogen receptor beta and the induction of Mn-superoxide dismutase. Phytochemistry 2014, 98:164-173.
381. Rosario E.R., Carroll J., Pike C.J. Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res. 2010, 1359:281-290.
382. Routledge E.J., Sumpter J.P. Structural features of alkylphenolic chemicals associated with estrogenic activity. J. Biol. Chem. 1997, 272(6):3280-3288.
383. Rowlands D.J., Chapple S., Siow R.C., Mann G.E. Equol-stimulated mitochondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: roles for F-actin and GPR30. Hypertension 2011, 57(4):833-840.
384. Ruh M.F., Zacharewski T., Connor K., Howell J., Chen I., Safe S. Naringenin: a weakly estrogenic bioflavonoid that exhibits antiestrogenic activity. Biochem. Pharmacol. 1995, 50(9):1485-1493.
385. Sabatucci J.P., Ashwell M.A., Trybulski E., O'Donnell M.M., Moore W.J., Harnish D.C., Chadwick C.C. Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16(4):854-858.
386. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm. 2001, 62:231-252.
387. Safe S., Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. Chem. Res. Toxicol. 2003, 16(7):807-816.
388. Safe S.H., Pallaroni L., Yoon K., Gaido K., Ross S., Saville B., McDonnell D. Toxicology of environmental estrogens. Reprod. Fertil. Dev. 2001, 13(4):307-315.
389. Saggar J.K., Chen J., Corey P., Thompson L.U. The effect of secoisolariciresinol diglucoside and flaxseed oil, alone and in combination, on MCF-7 tumor growth and signaling pathways. Nutr. Cancer 2010, 62(4):533-542.
390. Santen R.J., Fan P., Zhang Z., Bao Y., Song R.X., Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 2009, 74(7):586-594.
391. Santolla M.F., De Francesco E.M., Lappano R., Rosano C., Abonante S., Maggiolini M. Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cell. Signal. 2014, 26(7):1466-1475.
392. Sauvé K., Lepage J., Sanchez M., Heveker N., Tremblay A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res. 2009, 69(14):5793-5800.
393. Schlange T., Matsuda Y., Lienhard S., Huber A., Hynes N.E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007, 9(5):R63.
394. Schmidt J.M., Mercure J., Tremblay G.B., Pagé M., Kalbakji A., Feher M., Dunn-Dufault R., Peter M.G., Redden P.R. De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. J. Med. Chem. 2003, 46(8):1408-1418.
395. Schultz T.W., Sinks G.D., Cronin M.T. Structure-activity relationships for gene activation oestrogenicity: evaluation of a diverse set of aromatic chemicals. Environ. Toxicol. 2002, 17(1):14-23.
396. Schwartz-Mittelman A., Baruch A., Neufeld T., Buchner V., Rishpon J. Electrochemical detection of xenoestrogenic and antiestrogenic compounds using a yeast two-hybrid-17-beta-estradiol system. Bioelectrochemistry 2005, 65(2):149-156.
397. Sharan S., Nikhil K., Roy P. Effects of low dose treatment of tributyltin on the regulation of estrogen receptor functions in MCF-7 cells. Toxicol. Appl. Pharmacol. 2013, 269(2):176-186.
398. Shelly W., Draper M.W., Krishnan V., Wong M., Jaffe R.B. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv. 2008, 63(3):163-181.
399. Shen K., Leung S.W., Ji L., Huang Y., Hou M., Xu A., Wang Z., Vanhoutte P.M. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Biochem. Pharmacol. 2014, 88(1):66-74.
400. Shi C., Zheng D.D., Fang L., Wu F., Kwong W.H., Xu J. Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim. Biophys. Acta 2012, 1820(4):453-460.
401. Shimamura N., Miyase T., Umehara K., Warashina T., Fujii S. Phytoestrogens from Aspalathus linearis. Biol. Pharm. Bull. 2006, 29(6):1271-1274.
402. Shin J.E., Bae E.A., Lee Y.C., Ma J.Y., Kim D.H. Estrogenic effect of main components kakkalide and tectoridin of Puerariae Flos and their metabolites. Biol. Pharm. Bull. 2006, 29(6):1202-1206.
403. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 2006, 6(10):813-823.
404. Sibonga J.D., Bell N.H., Turner R.T. Evidence that ibuprofen antagonizes selective actions of estrogen and tamoxifen on rat bone. J. Bone Miner. Res. 1998, 13(5):863-870.
405. Silva E., Kabil A., Kortenkamp A. Cross-talk between non-genomic and genomic signalling pathways-distinct effect profiles of environmental estrogens. Toxicol. Appl. Pharmacol. 2010, 245(2):160-170.
406. Simões B.M., Vivanco M.D. Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen. Future Oncol. 2011, 7(8):995-1006.
407. Simoncini T., Lenzi E., Zöchling A., Gopal S., Goglia L., Russo E., Polak K., Casarosa E., Jungbauer A., Genazzani A.D., Genazzani A.R. Estrogen-like effects of wine extracts on nitric oxide synthesis in human endothelial cells. Maturitas 2011, 70(2):169-175.
408. Sirianni R., Chimento A., De Luca A., Casaburi I., Rizza P., Onofrio A., Iacopetta D., Puoci F., Andò S., Maggiolini M., Pezzi V. Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation. Mol. Nutr. Food Res. 2010, 54(6):833-840.
409. Soltysik K., Czekaj P. Membrane estrogen receptors - is it an alternative way of estrogen action?. J. Physiol. Pharmacol. 2013, 64(2):129-142.
410. Somers-Edgar T.J., Scandlyn M.J., Stuart E.C., Le Nedelec M.J., Valentine S.P., Rosengren R.J. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 2008, 122(9):1966-1971.
411. Somjen D., Knoll E., Vaya J., Stern N., Tamir S. Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 2004, 91(3):147-155.
412. Somjen D., Kohen F., Gayer B., Knoll E., Limor R., Baz M., Sharon O., Posner G.H., Stern N. A non-calcemic Vitamin D analog modulates both nuclear and putative membranal estrogen receptors in cultured human vascular smooth muscle cells. J. Steroid Biochem. Mol. Biol. 2004, 89-90(1-5):397-399.
413. Somjen D., Katzburg S., Knoll E., Hendel D., Stern N., Kaye A.M., Yoles I. DT56a (Femarelle): a natural selective estrogen receptor modulator (SERM). J. Steroid Biochem. Mol. Biol. 2007, 104(3-5):252-258.
414. Song T.T., Hendrich S., Murphy P.A. Estrogenic activity of glycitein, a soy isoflavone. J. Agric. Food Chem. 1999, 47(4):1607-1610.
415. Song L.H., Pan W., Yu Y.H., Quarles L.D., Zhou H.H., Xiao Z.S. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol. In Vitro 2006, 20(6):915-922.
416. Song L., Zhao J., Zhang X., Li H., Zhou Y. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur. J. Pharmacol. 2013, 714(1-3):15-22.
417. Sonneveld E., Jansen H.J., Riteco J.A., Brouwer A., van der Burg B. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. Toxicol. Sci. 2005, 83(1):136-148.
418. Soto A.M., Sonnenschein C., Chung K.L., Fernandez M.F., Olea N., Serrano F.O. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ. Health Perspect. 1995, 103(Suppl. 7):113-122.
419. Sotoca A.M., Gelpke M.D., Boeren S., Ström A., Gustafsson J.Å., Murk A.J., Rietjens I.M., Vervoort J. Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol. Cell. Proteomics 2011, 10(1). (M110.002170).
420. Stauffer S.R., Coletta C.J., Tedesco R., Nishiguchi G., Carlson K., Sun J., Katzenellenbogen B.S., Katzenellenbogen J.A. Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J. Med. Chem. 2000, 43(26):4934-4947.
421. Steinmetz R., Young P.C., Caperell-Grant A., Gize E.A., Madhukar B.V., Ben-Jonathan N., Bigsby R.M. Novel estrogenic action of the pesticide residue beta-hexachlorocyclohexane in human breast cancer cells. Cancer Res. 1996, 56(23):5403-5409.
422. Stice J.P., Mbai F.N., Chen L., Knowlton A.A. Rapid activation of nuclear factor κB by 17β-estradiol and selective estrogen receptor modulators: pathways mediating cellular protection. Shock 2012, 38(2):128-136.
423. 2+ efflux from rat hepatocytes. J. Biol. Chem. 2010, 285(35):27201-27212.
424. Suenaga F., Hatsushika K., Takano S., Ando T., Ohnuma Y., Ogawa H., Nakao A. A possible link between resveratrol and TGF-beta: resveratrol induction of TGF-beta expression and signaling. FEBS Lett. 2008, 582(5):586-590.
425. Sultankulova K.T., Chervyakova O.V., Kozhabergenov N.S., Shorayeva K.A., Strochkov V.M., Orynbayev M.B., Sandybayev N.T., Sansyzbay A.R., Vasin A.V. Comparative evaluation of effectiveness of IAVchip DNA microarray in influenza A diagnosis. Sci. World J. 2014, 2014:620580.
426. Sun H., Chen W., Xu X., Ding Z., Chen X., Wang X. Pyrethroid and their metabolite, 3-phenoxybenzoic acid showed similar (anti)estrogenic activity in human and rat estrogen receptor α-mediated reporter gene assays. Environ. Toxicol. Pharmacol. 2014, 37(1):371-377.
427. Swami S., Krishnan A.V., Peng L., Lundqvist J., Feldman D. Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements. Endocr. Relat. Cancer 2013, 20(4):565-577.
428. Swedenborg E., Rüegg J., Hillenweck A., Rehnmark S., Faulds M.H., Zalko D., Pongratz I., Pettersson K. 3-Methylcholanthrene displays dual effects on estrogen receptor (ER) alpha and ER beta signaling in a cell-type specific fashion. Mol. Pharmacol. 2008, 73(2):575-586.
429. Sweet F. Boron estrogens: synthesis, biochemical and biological testing of estrone and estradiol-17 beta 3-carboranylmethyl ethers. Steroids 1981, 37(2):223-238.
430. Takahashi Y., Hursting S.D., Perkins S.N., Wang T.C., Wang T.T. Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol. Carcinog. 2006, 45(1):18-25.
431. Takeda S. δ(9)-tetrahydrocannabinol targeting estrogen receptor signaling: the possible mechanism of action coupled with endocrine disruption. Biol. Pharm. Bull. 2014, 37(9):1435-1438.
432. Takemura H., Shim J.Y., Sayama K., Tsubura A., Zhu B.T., Shimoi K. Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro. J. Steroid Biochem. Mol. Biol. 2007, 103(2):170-177.
433. Tamir S., Eizenberg M., Somjen D., Stern N., Shelach R., Kaye A., Vaya J. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res. 2000, 60(20):5704-5709.
434. Taneda S., Mori Y., Kamata K., Hayashi H., Furuta C., Li C., Seki K., Sakushima A., Yoshino S., Yamaki K., Watanabe G., Taya K., Suzuki A.K. Estrogenic and anti-androgenic activity of nitrophenols in diesel exhaust particles (DEP). Biol. Pharm. Bull. 2004, 27(6):835-837.
435. Tange S., Fujimoto N., Uramaru N., Sugihara K., Ohta S., Kitamura S. In vitro metabolism of cis- and trans-permethrin by rat liver microsomes, and its effect on estrogenic and anti-androgenic activities. Environ. Toxicol. Pharmacol. 2014, 37(3):996-1005.
436. Tanji M., Kiyama R. Expression profiling of estrogen responsive genes using genomic and proteomic techniqes for the evaluation of endocrine disruptors. Curr. Pharmacogenomics 2004, 2(3):255-266.
437. Taylor S.E., Martin-Hirsch P.L., Martin F.L. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett. 2010, 288(2):133-148.
438. ter Veld M.G., Schouten B., Louisse J., van Es D.S., van der Saag P.T., Rietjens I.M., Murk A.J. Estrogenic potency of food-packaging-associated plasticizers and antioxidants as detected in ERalpha and ERbeta reporter gene cell lines. J. Agric. Food Chem. 2006, 54(12):4407-4416.
439. Thakkar J.P., Mehta D.G. A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 2011, 16(3):276-285.
440. Thasni K.A., Rakesh S., Rojini G., Ratheeshkumar T., Srinivas G., Priya S. Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. Ann. Oncol. 2008, 19(4):696-705.
441. Thasni K.A., Ratheeshkumar T., Rojini G., Sivakumar K.C., Nair RS G.S., Banerji A., Somasundaram V., Srinivas P. Structure activity relationship of plumbagin in BRCA1 related cancer cells. Mol. Carcinog. 2013, 52(5):392-403.
442. Thomas P., Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol. 2006, 102(1-5):175-179.
443. Thongprakaisang S., Thiantanawat A., Rangkadilok N., Suriyo T., Satayavivad J. Glyphosate induces human breast cancer cells growth via estrogen receptors. Food Chem. Toxicol. 2013, 59:129-136.
444. Tian Y., Ke S., Thomas T., Meeker R.J., Gallo M.A. Regulation of estrogen receptor mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin as measured by competitive RT-PCR. J. Biochem. Mol. Toxicol. 1998, 12(2):71-77.
445. Tian H., Ru S., Wang Z., Cai W., Wang W. Estrogenic effects of monocrotophos evaluated by vitellogenin mRNA and protein induction in male goldfish (Carassius auratus). Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2009, 150(2):231-236.
446. Tian J., Berton T.R., Shirley S.H., Lambertz I., Gimenez-Conti I.B., DiGiovanni J., Korach K.S., Conti C.J., Fuchs-Young R. Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice. J. Clin. Invest. 2012, 122(1):192-204.
447. Tilley A.J., Zanatta S.D., Qin C.X., Kim I.K., Seok Y.M., Stewart A., Woodman O.L., Williams S.J. 2-Morpholinoisoflav-3-enes as flexible intermediates in the synthesis of phenoxodiol, isophenoxodiol, equol and analogues: vasorelaxant properties, estrogen receptor binding and Rho/RhoA kinase pathway inhibition. Bioorg. Med. Chem. 2012, 20(7):2353-2361.
448. Tohno H., Horii C., Fuse T., Okonogi A., Yomoda S. Evaluation of estrogen receptor Beta binding of pruni cortex and its constituents. Yakugaku Zasshi 2010, 130(7):989-997.
449. Tolba M.F., Esmat A., Al-Abd A.M., Azab S.S., Khalifa A.E., Mosli H.A., Abdel-Rahman S.Z., Abdel-Naim A.B. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. IUBMB Life 2013, 65(8):716-729.
450. Tollefsen K.E., Nilsen A.J. Binding of alkylphenols and alkylated non-phenolics to rainbow trout (Oncorhynchus mykiss) hepatic estrogen receptors. Ecotoxicol. Environ. Saf. 2008, 69(2):163-172.
451. Toran-Allerand C.D., Guan X., MacLusky N.J., Horvath T.L., Diano S., Singh M., Connolly E.S., Nethrapalli I.S., Tinnikov A.A. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci. 2002, 22(19):8391-8401.
452. Toran-Allerand C.D., Tinnikov A.A., Singh R.J., Nethrapalli I.S. 17Alpha-estradiol: a brain-active estrogen?. Endocrinology 2005, 146(9):3843-3850.
453. Totta P., Acconcia F., Leone S., Cardillo I., Marino M. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life 2004, 56(8):491-499.
454. Tran D.Q., Ide C.F., McLachlan J.A., Arnold S.F. The anti-estrogenic activity of selected polynuclear aromatic hydrocarbons in yeast expressing human estrogen receptor. Biochem. Biophys. Res. Commun. 1996, 229(1):101-108.
455. Tsai K.S., Yang R.S., Liu S.H. Benzo[a]pyrene regulates osteoblast proliferation through an estrogen receptor-related cyclooxygenase-2 pathway. Chem. Res. Toxicol. 2004, 17(5):679-684.
456. Uchida M., Nakamura H., Kagami Y., Kusano T., Arizono K. Estrogenic effects of o, p'-DDT exposure in Japanese medaka (Oryzias latipes). J. Toxicol. Sci. 2010, 35(4):605-608.
457. Ullrich J.W., Unwalla R.J., Singhaus R.R., Harris H.A., Mewshaw R.E. Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones. Bioorg. Med. Chem. Lett. 2007, 17(1):118-122.
458. 2+ influx and contraction in murine cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 294(6):H2421-H2427.
459. Umehara K., Nemoto K., Kimijima K., Matsushita A., Terada E., Monthakantirat O., De-Eknamkul W., Miyase T., Warashina T., Degawa M., Noguchi H. Estrogenic constituents of the heartwood of Dalbergia parviflora. Phytochemistry 2008, 69(2):546-552.
460. Uslu U., Sandal S., Cumbul A., Yildiz S., Aydin M., Yilmaz B. Evaluation of estrogenic effects of polychlorinated biphenyls and organochlorinated pesticides using immature rat uterotrophic assay. Hum. Exp. Toxicol. 2013, 32(5):476-482.
461. Valero M.S., Pereboom D., Barcelo-Batllory S., Brines L., Garay R.P., Alda J.O. Protein kinase A signalling is involved in the relaxant responses to the selective β-oestrogen receptor agonist diarylpropionitrile in rat aortic smooth muscle in vitro. J. Pharm. Pharmacol. 2011, 63(2):222-229.
462. Vallejo G., Ballaré C., Barañao J.L., Beato M., Saragüeta P. Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells. Mol. Endocrinol. 2005, 19(12):3023-3037.
463. van Aswegen C., Dirksen van Schalkwyk J.C., Roux L.J., Becker P.J., Du Plessis D.J. A novel study on the effect of acetylsalicylic acid on the binding capacity of estrogen receptors from MCF-7 cells. Clin. Physiol. Biochem. 1992, 9(4):145-149.
464. Vasconsuelo A., Pronsato L., Ronda A.C., Boland R., Milanesi L. Role of 17β-estradiol and testosterone in apoptosis. Steroids 2011, 76(12):1223-1231.
465. Ventura C., Núñez M., Miret N., Martinel Lamas D., Randi A., Venturino A., Rivera E., Cocca C. Differential mechanisms of action are involved in chlorpyrifos effects in estrogen-dependent or -independent breast cancer cells exposed to low or high concentrations of the pesticide. Toxicol. Lett. 2012, 213(2):184-193.
466. Vermerris W., Nicholson R.L. Phenolic Compound Biochemistry 2008, Springer.
467. Villa E. Role of estrogen in liver cancer. Womens Health (Lond. Engl.) 2008, 4:41-50.
468. Virgili F., Acconcia F., Ambra R., Rinna A., Totta P., Marino M. Nutritional flavonoids modulate estrogen receptor alpha signaling. IUBMB Life 2004, 56(3):145-151.
469. Vo N.T., Madlener S., Bago-Horvath Z., Herbacek I., Stark N., Gridling M., Probst P., Giessrigl B., Bauer S., Vonach C., Saiko P., Grusch M., Szekeres T., Fritzer-Szekeres M., Jäger W., Krupitza G., Soleiman A. Pro- and anticarcinogenic mechanisms of piceatannol are activated dose dependently in MCF-7 breast cancer cells. Carcinogenesis 2010, 31(12):2074-2081.
470. Vo T.T., Jung E.M., Choi K.C., Yu F.H., Jeung E.B. Estrogen receptor α is involved in the induction of Calbindin-D(9k) and progesterone receptor by parabens in GH3 cells: a biomarker gene for screening xenoestrogens. Steroids 2011, 76(7):675-681.
471. von Angerer E., Kranzfelder G., Taneja A.K., Schönenberger H. N, N'-dialkylbis(dichlorophenyl)ethylenediamines and -imidazolidines: relationship between structure and estradiol receptor affinity. J. Med. Chem. 1980, 23(12):1347-1350.
472. Wada H., Tarumi H., Imazato S., Narimatsu M., Ebisu S. In vitro estrogenicity of resin composites. J. Dent. Res. 2004, 83(3):222-226.
473. Wagner J., Lehmann L. Estrogens modulate the gen\e expression of Wnt-7a in cultured endometrial adenocarcinoma cells. Mol. Nutr. Food Res. 2006, 50(4-5):368-372.
474. Walters M.R., Sharma R. Cross-talk between beta-adrenergic stimulation and estrogen receptors: isoproterenol inhibits 17beta-estradiol-induced gene transcription in A7r5 cells. J. Cardiovasc. Pharmacol. 2003, 42(2):266-274.
475. Wang L.Q. Mammalian phytoestrogens: enterodiol and enterolactone. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 777(1-2):289-309.
476. Wang R.Y., Needham L.L. Environmental chemicals: from the environment to food, to breast milk, to the infant. J. Toxicol. Environ. Health B Crit. Rev. 2007, 10(8):597-609.
477. Wang L.H., Yang X.Y., Mihalic K., Xiao W., Li D., Farrar W.L. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J. Biol. Chem. 2001, 276(34):31839-31844.
478. Wang X., Masri S., Phung S., Chen S. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res. 2008, 68(7):2259-2265.
479. Wang Y., Zhao Y., Chen X. Experimental study on the estrogen-like effect of boric Acid. Biol. Trace Elem. Res. 2008, 121(2):160-170.
480. Wang J., Chung M.H., Xue B., Ma H., Ma C., Hattori M. Estrogenic and antiestrogenic activities of phloridzin. Biol. Pharm. Bull. 2010, 33(4):592-597.
481. Wang L.M., Xie K.P., Huo H.N., Shang F., Zou W., Xie M.J. Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells. Asian Pac. J. Cancer Prev. 2012, 13(4):1431-1437.
482. Wang Y., Wang W.L., Xie W.L., Li L.Z., Sun J., Sun W.J., Gong H.Y. Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation. Phytomedicine 2013, 20(10):787-796.
483. Wang X., Deng H., Zou F., Fu Z., Chen Y., Wang Z., Liu L. ER-α36-mediated gastric cancer cell proliferation via the c-Src pathway. Oncol. Lett. 2013, 6(2):329-335.
484. Wang H., Guo Y., Zhao X., Li H., Fan G., Mao H., Miao L., Gao X. An estrogen receptor dependent mechanism of Oroxylin A in the repression of inflammatory response. PLoS One 2013, 8(7):e69555.
485. Wang Y., Zhou Q., Wang C., Yin N., Li Z., Liu J., Jiang G. Estrogen-like response of perfluorooctyl iodide in male medaka (Oryzias latipes) based on hepatic vitellogenin induction. Environ. Toxicol. 2013, 28(10):571-578.
486. Wang H., Gao M., Wang J. Kaempferol inhibits cancer cell growth by antagonizing estrogen-related receptor α and γ activities. Cell Biol. Int. 2013, 37(11):1190-1196.
487. Wang C., Xu C.X., Bu Y., Bottum K.M., Tischkau S.A. Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling. Carcinogenesis 2014, 35(3):703-713.
488. Watson C.S., Jeng Y.J., Kochukov M.Y. Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. FASEB J. 2008, 22(9):3328-3336.
489. Willemsen P., Scippo M.L., Kausel G., Figueroa J., Maghuin-Rogister G., Martial J.A., Muller M. Use of reporter cell lines for detection of endocrine-disrupter activity. Anal. Bioanal. Chem. 2004, 378(3):655-663.
490. Wintermantel T.M., Campbell R.E., Porteous R., Bock D., Gröne H.J., Todman M.G., Korach K.S., Greiner E., Pérez C.A., Schütz G., Herbison A.E. Definition of estrogen receptor pathway critical for estrogen positive feedback to gonadotropin-releasing hormone neurons and fertility. Neuron 2006, 52(2):271-280.
491. Wormke M., Stoner M., Saville B., Walker K., Abdelrahim M., Burghardt R., Safe S. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol. Cell. Biol. 2003, 23(6):1843-1855.
492. Wu K.L., Chen C.H., Shih C.D. Nontranscriptional activation of PI3K/Akt signaling mediates hypotensive effect following activation of estrogen receptor β in the rostral ventrolateral medulla of rats. J. Biomed. Sci. 2012, 19(1):76.
493. Wungsintaweekul B., Umehara K., Miyase T., Noguchi H. Estrogenic and anti-estrogenic compounds from the Thai medicinal plant, Smilax corbularia (Smilacaceae). Phytochemistry 2011, 72(6):495-502.
494. Xie L., Thrippleton K., Irwin M.A., Siemering G.S., Mekebri A., Crane D., Berry K., Schlenk D. Evaluation of estrogenic activities of aquatic herbicides and surfactants using an rainbow trout vitellogenin assay. Toxicol. Sci. 2005, 87(2):391-398.
495. Xing D., Nozell S., Chen Y.F., Hage F., Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler. Thromb. Vasc. Biol. 2009, 29(3):289-295.
496. Xu H., Qin S., Carrasco G.A., Dai Y., Filardo E.J., Prossnitz E.R., Battaglia G., Doncarlos L.L., Muma N.A. Extra-nuclear estrogen receptor GPR30 regulates serotonin function in rat hypothalamus. Neuroscience 2009, 158(4):1599-1607.
497. Yamada T., Kunimatsu T., Sako H., Yabushita S., Sukata T., Okuno Y., Matsuo M. Comparative evaluation of a 5-day Hershberger assay utilizing mature male rats and a pubertal male assay for detection of flutamide's antiandrogenic activity. Toxicol. Sci. 2000, 53(2):289-296.
498. Yamada K., Terasaki M., Makino M. A novel estrogenic compound transformed from fenthion under UV-A irradiation. J. Hazard. Mater. 2010, 176(1-3):685-691.
499. Yang C., Chen S. Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999, 59(18):4519-4524.
500. Yao Y., Brodie A.M., Davidson N.E., Kensler T.W., Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res. Treat. 2010, 124(2):585-591.
501. Yeo S.H., Herbison A.E. Estrogen-negative feedback and estrous cyclicity are critically dependent upon estrogen receptor-α expression in the arcuate nucleus of adult female mice. Endocrinology 2014, 155(8):2986-2995.
502. Yoon K., Pallaroni L., Stoner M., Gaido K., Safe S. Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements. J. Steroid Biochem. Mol. Biol. 2001, 78(1):25-32.
503. Yoshitake J., Kato K., Yoshioka D., Sueishi Y., Sawa T., Akaike T., Yoshimura T. Suppression of NO production and 8-nitroguanosine formation by phenol-containing endocrine-disrupting chemicals in LPS-stimulated macrophages: involvement of estrogen receptor-dependent or -independent pathways. Nitric Oxide 2008, 18(3):223-228.
504. Yue W., Yager J.D., Wang J.P., Jupe E.R., Santen R.J. Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids 2013, 78(2):161-170.
505. Zacharewski T.R., Meek M.D., Clemons J.H., Wu Z.F., Fielden M.R., Matthews J.B. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters. Toxicol. Sci. 1998, 46(2):282-293.
506. Zhang X., Wang Y., Zhao Y., Chen X. Experimental study on the estrogen-like effect of mercuric chloride. Biometals 2008, 21(2):143-150.
507. Zhang X., Mukerji R., Samadi A.K., Cohen M.S. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells. BMC Complement. Altern. Med. 2011, 11:84.
508. Zhang S.Q., Sawmiller D., Li S., Rezai-Zadeh K., Hou H., Zhou S., Shytle D., Giunta B., Fernandez F., Mori T., Tan J. Octyl gallate markedly promotes anti-amyloidogenic processing of APP through estrogen receptor-mediated ADAM10 activation. PLoS One 2013, 8(8):e71913.
509. Zhang Q., Lu M., Wang C., Du J., Zhou P., Zhao M. Characterization of estrogen receptor α activities in polychlorinated biphenyls by in vitro dual-luciferase reporter gene assay. Environ. Pollut. 2014, 189:169-175.
510. Zhang X., Li J.H., Duan S.X., Lin Q.J., Ke S., Ma L., Huang T.H., Jiang X.W. G protein-coupled estrogen receptor-protein kinase A-ERK-CREB signaling pathway is involved in the regulation of mouse gubernaculum testis cells by diethylstilbestrol. Arch. Environ. Contam. Toxicol. 2014, 67(1):97-103.
511. Zhang X., Deng H., Wang Z.Y. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells. J. Steroid Biochem. Mol. Biol. 2014, 143C:434-443.
512. Zhou Y., Zhu Z.L., Guan X.X., Hou W.W., Yu H.Y. Reciprocal roles between caffeine and estrogen on bone via differently regulating cAMP/PKA pathway: the possible mechanism for caffeine-induced osteoporosis in women and estrogen's antagonistic effects. Med. Hypotheses 2009, 73(1):83-85.
513. Zhu Y., Sullivan L.L., Nair S.S., Williams C.C., Pandey A.K., Marrero L., Vadlamudi R.K., Jones F.E. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res. 2006, 66(16):7991-7998.